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Disease-associated mutations located in the protein coding exonic regions are in 
general classified as missense mutations supposedly affecting single amino acids. 
However, exonic mutations can potentially also affect mRNA splicing suggesting that 
a substantial portion of disease-associated mutations might have been misclassified 
in the past.  
Here, it was hypothesized that surprisingly differential phenotypes caused by 
similar mutations in the same gene and originally classified as missense mutations 
might originate from a differential impact on mRNA splicing. This hypothesis was 
evaluated using the example of two retinitis pigmentosa (RP) mutations in the 
rhodopsin gene which affect the same nucleotide but are linked to remarkably 
different phenotypes. The c.620T>G mutation is associated with a severe, early-
onset RP, whereas c.620T>A causes a mild, late-onset disease phenotype. In this 
study, I show that c.620T>G, in contrast to c.620T>A, creates an exceptionally strong 
splice acceptor site (SAS) resulting in a 90 bp in-frame deletion and protein 
mislocalization in vitro and in vivo. Furthermore, I could identify the core element 
responsible for the c.620T>G SAS strength. Finally, I demonstrate that this SAS is 
highly flexible in branch point choice, which could explain its remarkable strength. 
Apart from its role in pathogenicity, mRNA splicing is also playing an integrative 
part in some important biotechnological applications. This particularly applies to 
the process called mRNA trans-splicing that is capable of a seamless ligation of two 
separate mRNA molecules. Here, I investigated, whether mRNA trans-splicing can 
be used as a novel approach to overcome the limited genome packaging capacity of 
adeno-associated viral (AAV) vectors, which represents the most relevant limitation 
hindering their broad use for gene therapy. Current approaches addressing this 
issue focus on dual AAV vector strategies aiming at reconstitution of split genes at 
the genomic or at the protein level. However, these approaches harbor important 
disadvantages hampering their broad usage in therapeutically relevant contexts.  
To provide a proof of principle for reconstitution of split genes at the mRNA level, I 
developed a split fluorophore assay which allows for a convenient detection and 





key elements conferring high reconstitution efficiencies: the binding domain, which 
enables the tight interaction of two mRNA molecules, and the SAS facilitating the 
mRNA trans-splicing process. Using a combination of internally optimized binding 
domains and the remarkably strong c.620T>G SAS identified in the first part of this 
thesis very high reconstitution efficiencies up to 78 % were achieved in vitro. 
Moreover, by successfully applying this approach in the mouse retina, I provide a 
proof of principle for this technology in vivo. Finally, I show first evidence that mRNA 
trans-splicing can be utilized to reconstitute an important coding sequence 
exceeding the capacity of AAV vectors: the SpCas9-VPR module. 
This novel technology offers key advantages over currently used approaches and 






1.1 THE RETINA – A REMARKABLE SENSORY TISSUE 
1.1.1 Anatomy of the Retina 
The vertebrate retina is the part of the central nervous system enabling vision by 
turning light stimuli into electrical signal. This sensory tissue is constituting the 
innermost part of the eye and consists of five main neuronal cell types and their 
interconnecting synapses organized in different layers (Figure 1) (Hoon et al., 
2014). The cell bodies of the highly specialized, light-sensing photoreceptors are 
forming the outer nuclear layer (Müller, 1854). In the adjacent outer plexiform layer, 
they are synapsing on bipolar cells, which are in turn processing the photoreceptor 
input and relaying the information further to retinal ganglion cells (Euler et al., 
2014). The cell bodies of bipolar, horizontal, amacrine and Müller glia cells together 
form the inner nuclear layer of the retina. Horizontal cells are modulating the 
synaptic transmission between photoreceptors and bipolar cells. By providing 
inhibitory feedback to the photoreceptors, they are serving as a local gain control 
(Herrmann et al., 2011, Masland, 2012). Amacrine cells synapse onto bipolar and 
retinal ganglion cells thereby shaping and controlling ganglion cell responses 
(Baccus et al., 2008, Masland, 2001). By contrast, Müller glia cells are providing 
homeostatic and metabolic support to the retina. In the inner plexiform layer, 
bipolar cells are forming synapses with retinal ganglion cells, which are located in 
the ganglion cell layer. The axons of these cells are forming the optic nerve, leave the 
eye at the optic disc and transmit the visual information to higher processing areas 
in the brain. 
The mammalian retina is highly conserved across species (Wassle and Boycott, 
1991, Masland, 1996). One of its remarkable features is its inverted organization 
with the light-detecting photoreceptors in the outermost layer facing away from the 
entering light. There are two distinct types of photoreceptors, i.e. the rods and the 
cones (Schultze, 1866). Rods constitute 95 % of photoreceptors in the human retina 
and mediate dim light vision due to their high photon sensitivity (Curcio et al., 1990, 
Sampath and Rieke, 2004). By contrast, cone photoreceptors are facilitating central, 





central spot of the retina called macula. Cones are 100-fold less light sensitive than 
rods, however, their responses are highly wavelength-specific and are therefore 
mediating color discrimination (Nikonov et al., 2006).  
 
Figure 1 Schematic illustration of the retinal anatomy 
The identities of retinal cell types and morphology defining structures are indicated 
on the left. Adapted from (Webvision, 2011). 
Photoreceptors are compartmentalized cells, consisting of the light-sensitive outer 
segment (OS), an inner segment (IS) containing the organelles necessary for 
metabolism, a nucleus containing cell body and a synaptic terminal (Figure 2) 
(Carter-Dawson and LaVail, 1979). OS and IS are linked via a connecting cilium 
responsible for transport of cargo between these two compartments. The OS of rods 
and cones can easily be differentiated due to their distinct morphology. While rods 
are possessing long OS consisting of tightly stacked disks lacking a connection to the 
cell membrane, the shorter cone OS are composed of lamellar evaginations of the 
plasma membrane. The photoreceptor OS are embedded within the retinal pigment 
epithelium (RPE), which plays an important role in the maintenance of visual 





1.1.2 Phototransduction Cascade 
The conversion of detected light into an electrical signal taking place in rod and cone 
photoreceptors is referred to as the phototransduction cascade (Arshavsky et al., 
2002). As the signaling process is highly similar in both cell types, the rod 
phototransduction will be described exemplary in further detail (Figure 2). During 
darkness, the constant activity of transmembrane guanylyl cyclases (GCs) maintains 
high levels of cyclic guanosine monophosphate (cGMP) in the cytosol (Yang et al., 
1995). This cGMP is binding to cyclic nucleotide gated (CNG) channels keeping them 
in an open state and facilitating a constant influx of sodium (Na+) and calcium ions 
(Ca2+) called the dark current (Hagins et al., 1970). This continuous depolarization 
of the photoreceptor elicits a sustained glutamate transmitter release at the synapse 
during darkness.  
 
Figure 2 Morphology of a rod photoreceptor and its phototransduction 
cascade 
Left panel, Morphology of a rod photoreceptor. OS, outer segment. IS, inner segment. 
Right panel, Phototransduction cascade in a rod photoreceptor. High cGMP levels 
are maintained via guanylyl cyclases (GCs) keeping the CNG channels, composed of 
CNGA1 and CNGB1 subunits, in an open state. After detection of light, rhodopsin 
(RHO) is activated, which in turn activates the G-protein transducin (GT). The 
dissociation of its α-subunit stimulates the hydrolysis of cGMP by the 
phosphodiesterase 6 (PDE6), which leads to closure of CNG channels and a 





The process of vision begins with the detection of photons by the visual pigment, a 
G protein-coupled receptor (GPCR) called rhodopsin. This photopigment consists of 
the protein moiety opsin and the covalently bound chromophore 11-cis-retinal 
(Palczewski et al., 2000). After absorption of the photon, the 11-cis-retinal 
isomerizes into all-trans-retinal inducing conformational changes of rhodopsin into 
its active metarhodopsin II state. This in turn catalyzes an exchange of GDP with GTP 
at the heterotrimeric G-protein transducin. Subsequently, its α-subunit dissociates 
and stimulates the downstream effector cGMP phosphodiesterase 6 (PDE6). PDE6-
mediated hydrolysis of cGMP leads to closure of the CNG channels and a 
hyperpolarization of the photoreceptor. As a consequence, the glutamate 
transmitter release at the synapse is interrupted and responses in the second-order 
neurons, i.e. bipolar cells, are triggered (Luo et al., 2008, Michalakis et al., 2018). 
After initiating the phototransduction cascade, the bleached photopigment needs to 
be recovered. To first inactivate metarhodopsin II, the protein is phosphorylated by 
the rhodopsin kinase and subsequently bound by arrestin. During these steps, the 
all-trans-retinal dissociates from the protein moiety and is regenerated within the 
retinoid visual cycle (Kiser et al., 2012). For this process, all-trans-retinal is reduced 
to all-trans-retinol via retinol dehydrogenases (RDHs). This step is further 
facilitated via the ATP-binding cassette transporter (ABCR), which moves all-trans-
retinal bound by phosphatidylethanolamine into reach of the RDHs and thereby 
accelerates the reduction of toxic retinaldehydes (Quazi et al., 2012). Subsequently, 
the reduced chromophore diffuses through the interphotoreceptor matrix into the 
RPE, where it is esterified, transformed into 11-cis-retinol via the RPE-specific 65-
kDa protein (RPE65) and oxidized into 11-cis-retinal via RDHs. Back in the 
photoreceptor OS, the 11-cis-retinal initiates de-phosphorylation of the opsin and 
again becomes part of a fully functional rhodopsin photopigment. 
1.1.3 Inherited Retinal Diseases 
Inherited retinal diseases (IRDs) are a genetically and phenotypically 
heterogeneous group of disorders. They are the leading cause of blindness in people 
aged 15 to 45 and have an estimated prevalence of 1 in 1,500 – 1 in 3,000 (Bundey 





affected retinal cell type, i.e. rod or cone photoreceptors, and according to the state 
of disease progression.  
The most common progressive IRD predominantly affecting cones is the Stargardt 
macular dystrophy displaying a prevalence of 1 in 8,000 – 1 in 10,000 (Tanna et al., 
2017). It is characterized by an onset in childhood or early adolescence and leads to 
a degeneration of the macula thereby resulting in a loss of central vision. It is 
inherited in an autosomal recessive manner and it is mostly caused by mutations in 
the ABCA4 gene encoding the retinal transporter ABCR (Fujinami et al., 2013).  
With a prevalence of 1 in 4,000, the most common IRD primarily affecting rod 
photoreceptors is retinitis pigmentosa (RP). RP is a progressive disease leading to 
night blindness and tunnel vision (Hartong et al., 2006). In later stages, secondary 
cone photoreceptor cell death is induced eventually resulting in complete vision 
loss. However, the severity of the symptoms, rate of progression and age of onset 
show a striking variability in this disease. Depending on the affected gene and the 
nature of the mutation, retinitis pigmentosa can be inherited in a non-syndromic 
form as an autosomal dominant (12 – 35 %), autosomal recessive (40 – 60 %) or X-
linked trait (4 – 15 %) (Grondahl, 1987, Ayuso et al., 1995, Bravo-Gil et al., 2017). 
Moreover, this dystrophy can occur in combination with other non-ocular 
symptoms as part of a syndrome. The most frequent syndromic form is the Usher 
syndrome accounting for 30 – 40 % of all autosomal recessive retinitis pigmentosa 
(arRP) cases (Boughman et al., 1983). It is characterized by progressive visual 
impairment in combination with partial or total hearing loss and, in some cases, 
abnormalities of the vestibular system.  
One of the first loci identified for autosomal dominant retinitis pigmentosa (adRP) 
was the rhodopsin encoding gene (RHO) (Dryja et al., 1990). Up until now more than 
150 disease-causing mutations have been identified within this gene and, 
collectively, they represent the most common cause for adRP by far (Athanasiou et 
al., 2018). Within this locus, the c.620T>G transversion located in RHO exon 3, which 
is causing a severe, early-onset form of adRP, has been identified early on (Farrar et 
al., 1992). Assuming that c.620T>G is a missense mutation replacing the methionine 
at position 207 with an arginine (Met207Arg), several studies addressed the 





2004, Hagemann et al., 2006, Aguila et al., 2009, Audo et al., 2010a, Rakoczy et al., 
2011, Maubaret et al., 2012, Zhou et al., 2012, Hernandez-Rodriguez et al., 2012, 
Hernandez-Rodriguez et al., 2013). Met207 has been identified in other GPCRs as a 
part of the ligand binding pocket and was found to be critical for binding of 11-cis-
retinal (Figure 3) (Ahuja et al., 2009, Moitra et al., 2012, Kimata et al., 2016). Two 
decades later, another adRP mutation affecting the same nucleotide, i.e. the 
c.620T>A transversion classified as Met207Lys, has been identified (Audo et al., 
2010a, Audo et al., 2010b). Intriguingly, this mutation, despite supposedly altering 
the same amino acid as c.620T>G, results in a mild, late onset disease variant. These 
two mutations strikingly illustrate the adRP phenotype variability and highlight the 
importance for elucidating the underlying molecular mechanisms. 
 
Figure 3 Position and function of Met207 in rhodopsin 
A, Rhodopsin topology. Left panel, Schematic illustration of the molecular structure 
of rhodopsin. The region encoded by RHO exon 3, highlighted by a red dashed 
rectangle, comprises the second extracellular loop (EL2) and the transmembrane 
helix domain 5 (H5).  Right panel, Magnification of the exon 3-encoded region. The 
position of methionine 207 (Met207) is indicated by a red arrow. B, Stick model 
showing the 11-cis-retinal binding pocket. The glycines at position 114 (Gly114) and 
188 (Gly188) as well as Met207 play a crucial role. H3: transmembrane helix domain 






1.2 SPLICING – THE ART OF REMOVING INTRONS 
1.2.1 The Splicing Mechanism 
Most eukaryotic genes contain non-coding introns, which must be removed from the 
precursor messenger RNA (pre-mRNA) to generate a translatable mature 
messenger RNA (mRNA) in a process called ‘splicing’. Pre-mRNA splicing has been 
discovered more than 40 years ago and has since then been an important field of 
research (Berget et al., 1977). The process has mostly been investigated in 
Saccharomyces cerevisiae and later in Schizosaccharomyces pombe, which resembles 
the complex splicing mechanism found in human cells more closely (Hossain and 
Johnson, 2014, Stepankiw et al., 2015). Splicing is mediated via a large 
ribonucleoprotein complex, the spliceosome, which consists of five conserved small 
nuclear ribonucleoproteins (snRNPs), i.e. U1, U2, U4, U5 and U6 snRNP, and more 
than 300 proteins. The spliceosome assembles and disassembles for each intron in 
a highly dynamic process. For this purpose, specific splicing sequences need to be 
recognized: the 5’ splice donor site (SDS) marking the end of the 5’ exon and the 
beginning of the intron and the 3’ splice acceptor site (SAS) indicating the end of the 
intron and the beginning of the 3’ exon.  A functional SAS requires three distinct 
elements, which are usually located within a range of approximately 50 bp (Gao et 
al., 2008): a branch point (BP) sequence, a polypyrimidine tract (PPT) and the splice 
acceptor site. The canonical human consensus sequences for each element can be 
found in Table 1 (Zhang, 1998, Lim and Burge, 2001, Gao et al., 2008). 
Table 1 Canonical consensus sequences of human splice elements 
Splice element Consensus sequence 
Splice donor site mAG|GUrAGU 
Branch point yUnAy 
Polypyrimidine tract and splice acceptor site (y)11nCAG|G 
y = pyrimidine, r = purine, n = nucleotide, m = adenine or cytosine; | marks the 
junction between an exon and an intron; the branch point nucleotide is depicted as 





Each splicing cycle consists of two transesterification reactions (Figure 4) (Shi, 
2017). For the first reaction, known as branching, the branch point adenosine 
attacks the phosphate bond at the 5’ exon-intron junction. This results in the 
formation of an intronic lariat-3’ exon intermediate and a free 5’ exon end. In the 
second reaction, called exon ligation, the free end of the 5’ exon attacks the 
phosphate at the intron-3’ exon junction causing a ligation of the two exons and a 
release of the intron lariat structure. 
 
Figure 4 Illustration of the splicing mechanism 
For splicing, several sequence elements are required, i.e. a splice donor site (SDS), a 
branch point (BP), a polypyrimidine tract (PPT) and a splice acceptor site (SAS). 
Upon recognition of these splicing elements, snRNPs assemble to form a functional 
spliceosome. Next, the branch point adenosine attacks the end of the 5’ exon and 
forms a lariat in a process called branching. The free OH group of the 5’ exon in turn 
attacks the 3’ exon thereby facilitating exon ligation and excision of the lariat. 
Moreover, the splicing reaction is regulated by auxiliary cis-acting splicing 
regulatory elements composed of up to ten nucleotides. According to their function 
and position, they can be categorized into exonic splice enhancers (ESEs), exonic 
splice silencers (ESSs), intronic splice enhancers (ISEs) and intronic splice silencers 





for promotion or prevention of exon inclusion and are therefore proposed to play 
an important role in alternative splicing (Wang et al., 2006). 
1.2.2 Mutations Affecting mRNA Splicing 
Disease-causing single nucleotide polymorphisms (SNPs) are commonly assumed to 
be missense or nonsense mutations located in coding regions and leading to single 
amino acid exchanges or premature stop codons, respectively. However, SNPs can 
also lie in exon-intron boundaries thereby affecting pre-mRNA splicing by 
abolishing existing cis-acting splicing elements (Figure 5) (Cartegni et al., 2002, 
Abramowicz and Gos, 2018). For example, SNPs can eliminate splice donor or 
acceptor sites, which often results in exon skipping. Such a mutation has been 
identified in the MIP gene causing autosomal dominant congenital cataract 
(Abramowicz and Gos, 2018).  
 
Figure 5 Single nucleotide polymorphisms affecting splicing 
Left panel, Positions of single nucleotide polymorphisms (SNPs) abolishing existing 
(red lightning) or creating novel (red star) cis-acting splicing elements. SAS, splice 
acceptor site (pink oval). SDS, splice donor site (purple oval). ISE, intronic splice 
enhancer (green box). ESE, exonic splice enhancer (green box). Right panel, possible 
effect of the respective SNPs on pre-mRNA splicing. 
Moreover, SNPs can disrupt existing exonic or intronic splice enhancers or silencers, 
which may lead to exon skipping, activation of cryptic splice sites or alterations in 
the frequency of specific splice isoforms. Such mutations have been identified for 





SNP is leading to exon 5 skipping, and in frontotemporal dementia with 
parkinsonism linked to chromosome 17 (FTDP-17), in which the frequency of 
different MAPT splice isoforms is disturbed (Nielsen et al., 2007, Niblock and Gallo, 
2012). Another mechanism by which SNPs influence splicing is the creation of novel 
splice sites within coding sequences leading to loss of exon fragments and possibly 
to frame-shifts (Figure 5). An example is a mutation in the PRPH2 gene creating an 
alternative SDS and a 90 nucleotide in-frame deletion in exon 2 (Becirovic et al., 
2016b). Finally, splicing mutations can create novel splice sites and regulatory 
elements deep within intronic regions (Scotti and Swanson, 2016) like in CLRN1, 
where an intronic Usher syndrome-causing SNP has been identified, which creates 
a novel SDS leading to the inclusion of a pseudoexon and a premature stop codon 
(Khan et al., 2017).  
1.2.3 mRNA Trans-Splicing 
Apart from the regular cis-splicing events described in 1.2.1, splicing can also occur 
in trans thereby combining two separate pre-mRNA molecules to create a non-co-
linear chimeric RNA (Lei et al., 2016). This process was first discovered in 
trypanosomes, in which a short leader was spliced to the 5’ end of a pre-mRNA (Van 
der Ploeg et al., 1982). Since then, trans-splicing events have been identified in many 
more species including Caenorhabditis elegans, Mus musculus and Homo sapiens 
(Krause and Hirsh, 1987, Hirano and Noda, 2004, Chuang et al., 2018). 
Depending on the nature of the two pre-mRNA molecules involved in the process, 
trans-splicing events can be categorized into three types: spliced leader (SL) trans-
splicing, intragenic trans-splicing and intergenic trans-splicing (Figure 6). SL trans-
splicing is a mechanism occurring at high frequencies, however, it is mainly present 
in lower eukaryotes such as nematodes (Hastings, 2005). Intragenic and intergenic 
trans-splicing events combine two pre-mRNA molecules originating from the same 
or from different genes, respectively. They are mainly present in non-SL species like 
insects or vertebrates and occur at much lower rates (Horiuchi et al., 2003, Li et al., 
2008a). In vertebrates, trans-spliced chimeric mRNAs are proposed to serve several 
physiological functions as protein coding or noncoding RNAs. For example, they are 
thought to play a role in gene expression regulation and pluripotency maintenance 





The trans-splicing process is expected to share most characteristics with cis-
splicing. For instance, the same splice sites can be used for trans- as well as cis-
splicing and splicing factors known to promote alternative splicing can also enhance 
trans-splicing frequency (Shao et al., 2012, Chuang et al., 2018). The trans-splicing 
mechanism has already been applied successfully in two independent treatment 
strategies for inherited diseases. The first approach is centered around a group I 
intron-based ribozyme, which is used to replace defective 3’ sequences of a pre-
mRNA with a contained non-mutated 3’ exon tag via trans-splicing (Byun et al., 
2003). For the second approach, called spliceosome-mediated mRNA trans-splicing 
(SMaRT), an exogenous pre-mRNA trans-splicing molecule (PTM) is introduced into 
the target cell and replaces a part of the mutated endogenous pre-mRNA (Dooley et 
al., 2018). 
 
Figure 6 Naturally occurring trans-splicing events 
Shown are cis-splicing as well as spliced leader (SL), intragenic and intergenic trans-
splicing events. Dashed lines represent splicing events. Mature mRNA is shown on 
the right side. 
1.3 GENE THERAPY – A WEAPON AGAINST GENETIC DISEASES 
1.3.1 A Brief History of Gene Therapy 
Nearly 50 years ago, gene therapy has for the first time been proposed as a 
treatment for human genetic diseases (Friedmann and Roblin, 1972). Its 





for genetic modification. In contrast to protein-based drugs, which require multiple 
infusions, gene therapy offers the advantage of a sustained protein expression in 
long-lived cells (Dunbar et al., 2018). First approaches mainly focused on the 
alleviation or correction of a genetic defect by delivering a wild type version of the 
mutated gene into the target cell. For this purpose, efficient and non-toxic gene 
delivery vectors were required. Pioneers in the field recognized the potential of 
mammalian viruses for efficient gene transfer and soon replication-deficient γ-
retroviral vectors were used for gene delivery into hematopoietic stem cells (HSCs) 
(Mann et al., 1983, Riviere et al., 1995). For a more efficient and controlled 
transduction, cells have been isolated and treated ex vivo followed by an 
engraftment back into the patient. However, due to their inability of transducing 
non-dividing cells and their increased risk of oncogenic mutagenesis, γ-retroviral 
vectors have nowadays been largely replaced by the less genotoxic lentiviruses for 
ex vivo gene therapy (Montini et al., 2009, Ribeil et al., 2017). 
Targeting organs more directly via in vivo delivery thereby avoiding the exertive and 
delicate collection, culture and transplantation of target cells has always been an 
attractive strategy. However, in vivo approaches depend on a safe and efficient 
delivery to the target organ and a tissue-specific gene expression. These 
requirements were met by the adeno-associated virus (AAV), a non-enveloped 
member of the Parvoviridae family. It consists of an icosahedral capsid containing 
single-stranded DNA and is natively replication-deficient (Kotterman et al., 2015). 
In the 1990s, AAVs have been shown to efficiently transduce skeletal muscle cells 
and yield a long-term transgene expression (Kessler et al., 1996).  
Building on this work, the ability of different naturally occurring AAV serotypes to 
specifically and efficiently transduce a variety of tissues including muscle, liver, 
brain and retinal cells has been discovered and improved by using artificially 
optimized capsids (Zhong et al., 2008). Another advantageous feature of AAVs was 
the fact that their DNA was predominantly non-integrating and instead existing as 
an episome in the target cell, which substantially decreases the risk of malignant 
transformation due to integration. A leap in the field has been achieved, when large 
scale recombinant AAV (rAAV) production protocols have been established further 





of the biggest drawbacks of rAAV based gene therapy, however, is their low genome 
packaging capacity of about 4.7 kb precluding them from treatment of defective 
genes with large coding sequences (Wu et al., 2010). Nevertheless, rAAV-mediated 
gene delivery is widely used for in vivo gene therapy and has already been applied 
successfully for treatment of several genetic diseases like for hemophilia B and for 
spinal muscular atrophy (Rangarajan et al., 2017, Mendell et al., 2017). 
In recent years, new possibilities have opened up in the field of gene therapy since 
the discovery of the universal applicability of the CRISPR-Cas system for targeted 
genome editing in 2012 (Jinek et al., 2012). With this technology, a Cas9 DNA 
endonuclease can be targeted to a specific locus in the genome using a 
programmable guide RNA (gRNA) and induce a double strand break in situ. When 
an additional exogenous donor DNA repair template is provided, homology-directed 
repair (HDR) can be induced offering the possibility to exchange and correct 
mutated regions of a gene (Mali et al., 2013). This prospect is especially important 
for treatment of dominant negative mutations, which need to be eliminated to 
achieve sufficient rescue. However, HDR is an event of noticeably low efficiency and 
is virtually absent in postmitotic cells (Lino et al., 2018).  
Lately, another promising strategy based on CRISPR-Cas9 technology has been 
developed. The catalytically inactive “dead” Cas9 (dCas9) has been fused to various 
effector domains like adenine base editors or transcriptional regulators to modulate 
the human genome (Chavez et al., 2015, Yeo et al., 2018, Ryu et al., 2018). These 
novel techniques could be used to specifically modify single base pairs or to 
artificially switch genes off and on, which holds the potential to revolutionize the 
field of gene therapy once more. However, an application of these approaches in vivo 
still faces obstacles, as the coding sequences of the Cas9 fusion proteins evidently 
exceed the packaging limit of AAVs. Moreover, despite these new technologies 
offering exciting opportunities for human gene therapy, it needs to be stressed that 







1.3.2 Recombinant Adeno-Associated Virus-Mediated Gene 
Supplementation in the Retina 
Currently, rAAV-mediated gene supplementation is the most successful and most 
widely used gene therapy approach. For this treatment strategy, an entire gene 
expression cassette containing a promoter, a healthy copy of the mutated gene of 
interest and a polyadenylation signal (pA) flanked by inverted terminal repeats 
(ITR) is packaged into a rAAV and delivered into the target cell (Figure 7) (Boye et 
al., 2013). Subsequently, the wild type gene will be expressed, which renders this 
method particularly suitable for therapy of loss-of-function mutations.  
 
Figure 7 rAAV-mediated gene supplementation therapy 
For gene supplementation therapy, the gene of interest including all regulatory 
elements, i.e. a promoter (prom) and a polyadenylation signal (pA), flanked by 
inverted terminal repeats (ITR) is packaged into an AAV and delivered into the 
target cell, e.g. rod or cone photoreceptors. The size of the packaged sequence 
should not exceed 4.7 kb. 
There are several characteristics that make the eye an attractive target for gene 
therapy. First, the organ is small and highly compartmentalized, which allows for a 
local delivery of only a small vector dose (Smith et al., 2012). Second, the eye is 
immune privileged due to its anatomical structure, the presence of a blood-retinal-
barrier and the ocular microenvironment (Willett and Bennett, 2013, Trapani and 
Auricchio, 2018). Consequently, the risk of systemic vector dissemination and 
therefore the threat of immune responses against the vector or the transgene is 





mitotic cells, which allows for a stable and long-term transgene expression from 
non-integrating vectors after successful transduction. 
As most IRDs are caused by gene defects affecting photoreceptors or RPE cells (c.f. 
1.1.3), they represent the main target cell population for rAAV-mediated gene 
supplementation in the retina. To sufficiently transduce these cell types, two 
delivery routes are primarily used. Subretinal injections have already been shown 
early on to result in an efficient transduction, as they deliver the virus directly into 
proximity of RPE cells and photoreceptors (Ali et al., 1996). This transduction 
efficiency could even be improved by using pseudotyped viruses containing the AAV 
2 genome packaged into capsids of other serotypes, e.g. of AAV5 or AAV8, and by 
mutating specific tyrosine residues within the capsid (Natkunarajah et al., 2008, 
Petrs-Silva et al., 2011). Such variants like the AAV2/8 Y733F vector can efficiently 
transduce photoreceptors throughout the injected area after subretinal delivery 
(Koch et al., 2012). Intravitreal injection, the second route of administration, is 
considered to be technically less challenging and less invasive, as it does not rely on 
detachment of the retina from the RPE (Ochakovski et al., 2017). However, the virus 
needs to cross several retinal layers in order to infect photoreceptors and the highly 
concentrated vectors are diluted within the vitreous cavity (Igarashi et al., 2013). 
Therefore, AAV capsid variants mediating a highly efficient transduction while still 
possessing the ability to diffuse across the retinal layers are needed for this 
approach. 
rAAV-mediated gene supplementation therapy has been shown to successfully 
correct IRD phenotypes in various disease models, ranging from Gucy2e–/– mice, a 
model for the severe IRD Leber congenital amaurosis (LCA), to CNGB1-deficient 
dogs displaying a RP-like phenotype (Mihelec et al., 2011, Petersen-Jones et al., 
2018). Building on some of this work, the first gene supplementation therapy 
product, a rAAV delivering a wild type copy of RPE65, has been approved by the FDA 
for treatment of LCA in December 2017 (NatureBiotechnologyNews, 2018). By 
being successfully translated into an approved therapy product and by achieving 
proof-of-principle in more than 20 different IRD animal models, rAAV-mediated 
gene supplementation has substantially advanced the field of retinal gene therapy 





1.3.3 rAAV Dual Vector Strategies 
Despite its success story, rAAV-mediated gene supplementation is not suitable for 
treatment of all inherited diseases caused by loss-of-function mutations yet. As 
mentioned above, one major limitation of this approach is the AAV’s restricted 
packaging capacity (Wu et al., 2010). Therefore, diseases caused by mutated genes 
with coding sequences (CDSs) larger than 4 kb are currently precluded from 
treatment (McClements and MacLaren, 2017). However, many inherited diseases 
including hemophilia A, Duchenne muscular dystrophy (DMD) and IRDs can be 
caused by loss-of-function mutations in large genes (Oldenburg and El-Maarri, 2006, 
Goldstein and McNally, 2010, Tanna et al., 2017). For instance, a selection of IRD-
causing genes exceeding the packaging limit and consequently precluded from gene 
supplementation therapy can be found in Table 2 (Kersey et al., 2018, RetNet, 2019). 
Patients with mutations in one of these genes would therefore benefit greatly from 
novel gene therapeutic treatment strategies overcoming these restrictions. 
Table 2 IRD-causing genes exceeding the AAV packaging limit 
Gene CDS Length Associated IRD 
ABCA4 6.8 kb Stargardt macular dystrophy, arRP 
ADGRV1 19 kb Usher syndrome 
CACNA1F 5.9 kb Congenital stationary night blindness 
CDH23 10.1 kb Usher syndrome 
CEP290 7.4 kb Leber congenital amaurosis 
CRB1 4.2 kb arRP, Leber congenital amaurosis 
EYS 9.4 kb arRP 
KIAA1549 5.9 kb arRP 
MYO7A 6.6 kb Usher syndrome 
PCDH15 5.9 kb Usher syndrome 
RP1 6.5 kb adRP, arRP 
SNRNP200 6.4 kb adRP 






One option to circumvent this limitation would be to utilize other vectors such as 
lentiviruses, which possess a higher cargo capacity of about 8.5 kb while still 
yielding moderate titers (Kumar et al., 2001). However, these vectors show less 
ability to selectively transduce a subset of target cells when compared to AAVs (Peng 
et al., 2001). Moreover, they are less efficient in transducing the post-mitotic cells of 
the central nervous system and, due to their larger size, are less capable of diffusing 
through multi-layered structures such as the retina (Lipinski et al., 2014). Given 
these restrictions combined with the increased potential of lentiviruses to induce 
host immune responses and their mutagenic potential due to their integration into 
the host genome, it is considered worthwhile to develop suitable rAAV systems to 
accommodate the need for larger cargo size. 
Several groups have attempted to enforce packaging of genes larger than 4.7 kb into 
an AAV capsid thereby creating so-called oversized vectors (Wu et al., 2007, Allocca 
et al., 2008). However, this results in the packaging of fragmented transgenes, which 
will contain varying overlapping regions and by chance undergo homologous 
recombination in the target cell (Dong et al., 2010, Hirsch et al., 2010). Due to the 
heterogeneity of the packaged genomes, which impedes a definite characterization 
of the vectors, further progress of this approach towards a clinical application is 
rather unlikely (McClements and MacLaren, 2017). As a more attractive alternative, 
rAAV dual vector technologies have been developed, for which the CDS of a 
transgene is split into at least two parts and packaged into two or more separate 
rAAV vectors. After co-transduction of the target cell by the split genome vectors, 
the full-length CDS is reconstituted. Since AAVs show a high co-transduction 
efficiency of > 90 % in the retina, the efficient delivery of both halves into the same 
target cell is not expected to represent a limiting issue (Palfi et al., 2012, Becirovic 
et al., 2016a, Bohm et al., 2017). An efficient reconstitution of the two transgene 
halves, however, remains challenging. For several years since the development of 
rAAV dual vector systems, reconstitution has only been addressed at the DNA level 
and several strategies have been explored to improve this approach (Figure 8) 






Figure 8 Schematic depiction of different rAAV dual vector strategies  
Illustration of the different reconstitution strategies of the currently employed rAAV 
dual vector approaches. Gene of interest coding sequences are split into two halves 
(5’ CDS and 3’ CDS) and packaged into separate vectors (5’ vector and 3’ vector). For 
overlapping vectors, homologous recombination is facilitated via an overlapping 
sequence part. For trans-splicing vectors, genomic reconstitution is enabled via 
concatemerization. Remaining ITR sequences are removed at the mRNA level via cis-
splicing mediated by a splice donor (SDS) and acceptor site (SAS). Hybrid vectors 
combine the two strategies described above by reconstituting via a recombinogenic 
binding domain (BD) or concatemerization. Remaining ITR and/or BD sequences 
are removed at mRNA level via cis-splicing. For split intein vectors, both halves are 
transcribed and translated separately. Reconstitution is facilitated at the protein 
level via split intein mediated protein trans-splicing. ITR, inverted terminal repeats. 
prom, promoter. pA, polyadenylation signal. N/C-term prot, N/C-terminal protein 





One of these strategies is referred to as the overlapping approach. For this strategy, 
the two defined transgene halves contain a homologous overlapping region at the 3’ 
end of the 5’ half and at the 5’ end of the 3’ half, which initiates homologous 
recombination and thereby facilitates reconstitution of the full-length transgene 
(Halbert et al., 2002, Lopes et al., 2013). Here, the 5’-vector contains the 5’ half of the 
transgene driven by an appropriate promoter. The 3’-vector lacks any promoter, but 
contains the 3’ half of the transgene and a pA signal for mRNA stabilization and 
proper expression of the reconstituted protein. Another strategy called trans-
splicing approach does not possess a region of overlap, but instead is based on 
concatemerization, i.e. the formation of stable episomal structures by joining the 
flanking ITRs. This process can occur intramolecularly between the flanking ITRs of 
one episome as well as intermolecularly between different episomes (Chen et al., 
2001). Following this concatemerization, the ITR sequence still resides in between 
the two transgene halves and would therefore disrupt the open reading frame. To 
overcome this problem, a splice donor site (SDS) is placed at the 3’ end of the 5’ CDS 
and a splice acceptor site (SAS) is placed at the 5’ end of the 3’ CDS. After 
transcription, the full-length transgene will still contain (partial) sequences of the 
ITRs flanking the two CDSs, however, due to the presence of the splicing elements, 
this sequence will be removed from the mRNA via regular cis-splicing (Reich et al., 
2003, Lai et al., 2005). Therefore, although this strategy has been termed ‘trans-
splicing’ approach, mRNA splicing never actually takes place in trans. The last 
strategy based on genomic reconstitution is a fusion of the overlapping and the 
trans-splicing approach termed ‘hybrid approach’. For this purpose, a designated 
recombinogenic sequence, e.g. derived from the alkaline phosphatase or the F1-
phage, is employed. Moreover, the two transgene halves contain appropriate splice 
sites to remove the recombinogenic sequence from the mRNA after successful 
recombination (Ghosh et al., 2008, Trapani et al., 2015).  
Several studies set out to determine the differential efficiencies of the three 
strategies based on genomic reconstitution. All approaches have been reported to 
result in transgene reconstitution and expression in vivo and thereby mitigate 
disease phenotypes (Lai et al., 2005, Trapani et al., 2014, McClements et al., 2019). 
However, when comparing the strategies directly, contradictory results have been 





yields a more efficient reconstitution than the overlapping vectors, whereas 
Carvalho et al. showed that the overlapping approach dominates the trans-splicing 
strategy (Duan et al., 2001, Carvalho et al., 2017). Nevertheless, most studies 
concluded that the hybrid approach results in the best reconstitution efficiencies 
(Dyka et al., 2014, Colella et al., 2014, Carvalho et al., 2017).  
Still, all three approaches have limitations impeding an efficient reconstitution. The 
overlapping strategy, for instance, is most likely depending on reconstitution via 
homologous recombination – an event, which is rarely taking place in post-mitotic 
cells such as photoreceptors (Duan et al., 2001, Halbert et al., 2002, Fishel et al., 
2007). Accordingly, many studies have reported inefficient expression of the full-
length transgene in photoreceptors when using this approach (Lopes et al., 2013, 
Trapani et al., 2014, Carvalho et al., 2017). The trans-splicing strategy, on the other 
hand, is based on reconstitution via ITR-mediated concatemerization. However, in 
this process, self-circularization is preferred over intermolecular interaction (Duan 
et al., 1998, Choi et al., 2005). Moreover, the two transgene halves can concatemerize 
incorrectly, i.e. 5’ half – 5’ half, 3’ half – 3’ half or 3’ half – 5’ half, instead of forming 
the correct head-to-tail 5’ half – 3’ half concatemer (Schnepp et al., 2005). To 
overcome this issue, heterologous ITRs have been developed for an orientation-
directed concatemerization. However, this strategy seems to reduce the production 
yield of the vectors (Trapani et al., 2015). As the hybrid approach doubles the 
likelihood of successful reconstitution by combining both strategies, it also achieves 
the highest transgene expression levels. Still, the success rates obtained for the DNA-
based reconstitution systems are varying depending on the targeted cell type, the 
delivered transgene or the transduction efficiency of the AAV serotype (Duan et al., 
2001, Colella et al., 2014). Moreover, when the reconstitution efficiencies of all 
approaches are estimated in a quantitative, systematic experimental design, even 
the best approaches achieve only 17 % of the full-length transgene expression in 
vitro and 10 % in vivo (Carvalho et al., 2017). Although higher reconstitution 
efficiencies have been reported when using serotypes for ideal transduction in 
optimized model systems (Colella et al., 2014), the overall reported transgene 
expression levels remain disappointingly low (Duan et al., 2001, Trapani et al., 2014, 





Recently, another option for transgene reconstitution has been explored: split 
intein-mediated protein trans-splicing for reconstitution at the protein level (Figure 
8). Inteins are small internal protein elements found in microorganisms like 
bacteria, viruses or yeast. They are capable of excising themselves post-
translationally from their host proteins, analogous to intron splicing in the pre-
mRNA (Novikova et al., 2014). A subset of this group, called split inteins, possesses 
the ability to mediate the scarless ligation of two host proteins via protein trans-
splicing (Wu et al., 1998). For this, the N-terminal part of the intein (N-intein) is 
located on the C-terminal end of one protein, while the C-terminal part of the intein 
(C-intein) is positioned at the N-terminal end of the other protein. In 2008, split 
inteins have already been applied successfully for gene supplementation therapy of 
large genes (Li et al., 2008b). In this study, sequences encoding the cyanobacterial 
DnaB N-intein or C-intein have been fused to a split dystrophin cDNA. Both 
transgene halves were transcribed and translated separately, reconstituted at the 
protein level via protein trans-splicing and resulted in expression of dystrophin in a 
DMD mouse model. Recently, this method has been optimized further and 
successfully applied for treatment of IRDs yielding high transgene expression levels 
and outperforming DNA-based reconstitution systems (Tornabene et al., 2019). 
Moreover, this strategy has been used to deliver large fusion proteins such as the 
transcriptional activator Cas9-VPR into target cells in vivo (Chew et al., 2016). 
However, this system again comes with limitations. For split intein-mediated 
protein trans-splicing, the split site must contain either a cysteine, serine or 
threonine adjacent to the C-intein limiting the split site options. Moreover, the 
second amino acid residue adjacent to the split site also seems to influence the 
efficiency of the protein trans-splicing reaction (Stevens et al., 2017). Another 
important requirement for the selection of a suitable split site is that it is localized 
outside of structural domains to avoid improper protein folding. Consequently, 
several different split sites need to be screened for each transgene (Tornabene et al., 
2019) and it seems very likely that for many proteins, such split sites are not present 
in the central region of the respective coding sequences. Moreover, split inteins 
yielding the highest reconstitution efficiencies are derived from bacterial proteins, 
i.e. a subunit of DNA Polymerase III (DnaE) or a DNA helicase (DnaB) found in Nostoc 





2016). As transgene reconstitution via protein trans-splicing results in an equimolar 
production of inteins, this approach requires a thorough investigation regarding its 
potential to elicit host immune responses or to cause detrimental long-term toxic 
effects, e.g. due to accumulation in the target cell. In conclusion, despite recent 
advancement in the field of rAAV dual vector technology, there is still an unmet need 
for efficient and safe reconstitution of large genes. 
  




2 AIM OF THE STUDY 
Disease-associated mutations can act at the mRNA or at the protein level. Mutations 
located in the protein-coding exonic regions are generally classified as missense 
mutations expected to alter single amino acids. However, exonic mutations can 
potentially also affect mRNA splicing, which indicates that in the past a substantial 
portion of disease-associated mutations might have been misclassified. In this study, 
the hypothesis that differential phenotypes caused by similar mutations in the same 
gene originate from differential impact on mRNA splicing should be investigated (1). 
Moreover, apart from its role in pathogenicity, mRNA splicing is playing an 
integrative part in some important biotechnological applications. This particularly 
applies to the process called mRNA trans-splicing, which is enabling a seamless 
ligation of two separate mRNA molecules. In this study, it should be examined, 
whether mRNA trans-splicing could be used to overcome the limited genome 
packaging capacity of AAV vectors in a novel biotechnological approach (2). 
(1) The hypothesis should be evaluated using the example of two adRP 
mutations in the rhodopsin gene which affect the same nucleotide but are 
linked to remarkably different phenotypes. The c.620T>G mutation is 
associated with a severe, early-onset RP, whereas c.620T>A causes a mild, 
late-onset disease phenotype. The differential impact of both mutations 
should be tested at the mRNA and at the protein level in vitro and in vivo. 
(2) The limited genome packaging capacity of AAV vectors represents the most 
relevant limitation hampering their broad use for gene therapy. Current 
approaches addressing this issue focus on dual AAV vector strategies aiming 
at reconstitution of split genes at the genomic or at the protein level. 
However, these approaches harbor important disadvantages which hinder 
their broad usage in therapeutically relevant contexts. In this study, a novel 
dual vector technology should be developed aiming at a reconstitution at the 
mRNA level using mRNA trans-splicing. For this purpose, a split fluorophore 
assay will be established for testing and optimization in vitro. If successful, 
this method should be tested in vivo in the mouse retina and a proof of 
principle should be provided for the reconstitution of an important sequence 
exceeding the AAV packaging limit, i.e. the SpCas9-VPR module.  




3 MATERIALS & METHODS 
3.1 MATERIALS 
All chemicals used in this study hold a quality suitable for molecular biological 
applications and were obtained from Sigma-Aldrich, VWR, Roth, Merck or Fluka 
unless stated otherwise. All cell culture media and supplements were acquired from 
GibcoTM (Thermo Fisher Scientific) unless stated otherwise. For all buffers and 
reactions, highly pure deionized water obtained from the Milli-Q Plus System 
(Millipore) purified with 18.2 MΩ x cm (25 °C) was used. All materials used for cell 
culture applications were obtained in cell culture grade sterile wrapping or 
sterilized by autoclaving (Sterilisator, Münchener Medizin Mechanik). Bacterial 
growth medium was autoclaved prior to use.  
3.2 IN SILICO SPLICE PREDICTION ANALYSIS 
To predict the potential effects of single point mutations on splicing, the open access 
software tools Human Splicing Finder (HSF, http://www.umd.be/HSF/) and 
NNSplice (Berkeley Drosophila Genome Project, 
http://www.fruitfly.org/seq_tools/splice.html) were used. To predict the strength 
of different splice acceptor sites, the HSF, NNSplice and the Alternative Splice Site 
Predictor (ASSP, http://wangcomputing.com/assp/) were used. To obtain scores 
for branch point sequences, the HSF was used. 
3.3 CLONING 
3.3.1 Expression Vectors 
As expression system for in vitro experiments, the mammalian expression vector 
pcDNA3.1(+) containing a cytomegalovirus (CMV) promoter and a bovine growth 
hormone (bGH) polyadenylation signal (pA) was used. For in vivo expression, the 
genes of interest were cloned into a pAAV2.1 plasmid (Michalakis et al., 2010) 
containing a murine rhodopsin or CMV promoter, a SV40 or synthetic pA and 
flanking inverted terminal repeats (ITR). A list of the plasmids used in this study can 
be found in Table 3. The size of the transgene expression cassette within the flanking 




ITRs is indicated for each pAAV2.1 plasmid. The SP-dCas9-VPR plasmid was a gift 
from George Church (Addgene plasmid nr. 63798; http://n2t.net/addgene:63798; 
RRID: Addgene_63798). 






















pAAV2.1-mRho-RHO_WT-myc-SV40pA (4.55 kb within ITRs) 
pAAV2.1-mRho-RHO_c.620T>G-myc-SV40pA (4.55 kb within ITRs) 
pAAV2.1-mRho-RHO_c.620T>A-myc-SV40pA (4.55 kb within ITRs) 
pAAV2.1-CMV-Citrine-5’Cerulean_SDS_BD-synpA (1.70 kb within ITRs) 
pAAV2.1-CMV-BD_SAS_3’Cerulean-mCherry-synpA (2.07 kb within ITRs) 
pAAV2.1-4x-hU6-sgASCL1-CMV-dCas9N_SDS_BD-SV40pA (4.77 kb within ITRs) 




pAAV2.1-CMV-BD_SAS_dCas9C_VPR-synpA (4.62 kb within ITRs) 
SP-dCas9-VPR (Addgene plasmid nr. 63798) 
 
3.3.2 Standard Cloning Techniques 
For cloning, the classical restriction digest as well as the restriction enzyme 
independent NEBuilder cloning kit (New England Biolabs) and Gibson cloning 
(Gibson et al., 2009) were used. The genes of interest, i.e. the inserts to be cloned 
into the respective expression vectors, were either synthesized commercially 
(BioCat GmbH) or produced from existing plasmids via restriction digest or PCR. A 
detailed description for cloning and construction of minigenes has been published 
previously (Riedmayr et al., 2018). Moreover, small inserts up to 250 bp were 
synthesized via primer elongation. For this purpose, the insert sequence was split 
into two halves and constructed to contain a 20 bp overlapping region. The 
sequences were acquired from Eurofins Genomics with one sequence ordered in 
forward direction, the other in reverse direction. For primer elongation, the 
Herculase II fusion DNA polymerase (Agilent Technologies) was used in the 
following reaction mix: 
Herculase II primer elongation reaction mix 
5x Herculase II Reaction Buffer 5 µl   
dNTPs (10 mM)   1 µl 
Forward primer (100 µM)  1 µl 
Reverse primer (100 µM)  1 µl 
Herculase II DNA polymerase 0.5 µl 
H2O     ad 25 µl  
For amplification of the insert from an existing plasmid via PCR, primers containing 
appropriate restriction sites on the respective 5’ end were obtained from Eurofins 
Genomics. The Herculase II fusion DNA polymerase (Agilent Technologies) was used 
in the following reaction mix: 
 
 




Herculase II PCR reaction mix   
5x Herculase II Reaction Buffer 5 µl   
dNTPs (10 mM)   1 µl 
Forward primer (10 µM)  1 µl 
Reverse primer (10 µM)  1 µl 
Herculase II DNA polymerase 0.5 – 1 µl 
DNA template   1 – 30 ng 
H2O     ad 25 µl 
The primer elongation and PCR were run in a ProFlex PCR System Cycler (Applied 
Biosystems, Thermo Fisher Scientific) using the cycling conditions described in 
Table 4. The annealing temperature was calculated using the Thermo Fisher 
Scientific Tm Calculator. 
Table 4 Herculase II PCR and primer elongation cycling conditions 
If the parameter used for the PCR differs from the one used for the primer 
elongation, the primer elongation parameter is indicated in brackets. 
Step Number of cycles Temperature Duration 
Initial 
Denaturation 
1 95 °C 2 min 
Denaturation 
25 – 35 (2) 
95 °C 20 s 
Annealing 50 °C – 72 °C 30 s 
Elongation 72 °C 30 s/kb (30 s) 
Final Elongation 1 72 °C 3 min (1 min) 
Cooling 1 10 °C 15 min 
 
For the classical restriction digest, the desired vector as well as the insert were 
incubated using the appropriate restriction enzymes (Fermentas, Thermo Fisher 
Scientific) according to the manufacturer’s instructions. The resulting DNA 
fragments were separated on a 0.7 – 2 % agarose gel via gel electrophoresis run at 
150 V in 1x TBE buffer. 
 
 




1x TBE buffer       
0.5 M EDTA, pH 8.0     20.0 ml 
Boric acid      27.5 g 
Tris-(hydroxymethyl) aminomethane (Tris) 54.0 g 
H2O       ad 5 l 
The appropriate bands were excised and the DNA was extracted using the Qiaquick 
Gel Extraction kit (Qiagen) according to the manufacturer’s instructions. If 
necessary, the vector was dephosphorylated using the Rapid DNA Dephos & Ligation 
Kit (Roche) to prevent re-ligation. The same kit was used for ligation of the insert 
and the vector according to the provided protocol. The molar ratios of vector DNA 
to insert DNA used for the ligation ranged from 1:3 to 1:10. Weight to mole 
conversions were calculated using the open source software NEBioCalculator (New 
England Biolabs). 
For Gibson cloning and the NEBuilder cloning kit, the desired vector was digested 
using restriction enzymes, the fragments were separated on an agarose gel and the 
DNA was purified using the Qiaquick gel extraction kit. The insert was obtained 
commercially (Integrated DNA Technologies) or by primer elongation. 
Subsequently, the vector and insert were incubated in a self-made (Gibson cloning) 
or commercially acquired (NEBuilder cloning kit) reaction mix containing a 5’ 
exonuclease, a DNA polymerase and a ligase for 1 h at 50 °C. The molar ratios of 
vector to insert DNA ranged from 1:3 to 1:10. 
The ligated plasmids were transformed into chemically competent 10-beta 
Escherichia coli K12 bacteria (New England Biolabs). 5 µl of the ligation reaction or 
3 µl of the NEBuilder or Gibson cloning reaction mix were added to the bacteria, the 
solution was gently mixed by pipetting and chilled on ice for 30 min. Afterwards, a 
heat shock was applied for 30 – 45 s by placing the mixture in a Thermomixer 
compact (Eppendorf) at 42 °C. Subsequently, the bacteria were chilled on ice for 2 
min, plated onto a LB(+) agar plate containing 100 µg/ml ampicillin and incubated 
either at 37 °C in an incubator (Heraeus, Thermo Fisher Scientific) overnight or at 
RT for two days. 
 




LB(+) medium*    LB(+) agar plate   
Peptone  10 g   Agar   15 g 
Yeast extract  5 g   LB(+) medium ad 1 l 
NaCl   5 g   Ampicillin*  100 mg 
D-(+)-Glucose 1 g   *added after autoclaving 
H2O   ad 1 l 
*pH adjusted to 7.2 – 7.5 
For small-scale production of plasmid DNA, 5 ml LB(+) medium containing 100 
µg/ml ampicillin were inoculated with the respective bacteria and incubated at 37 
°C in a shaking incubator (Certomat IS, B. Braun Biotech International) at 225 rpm 
overnight. The plasmid DNA was extracted using an alkaline lysis-based protocol. 
For medium- and large-scale production of plasmid DNA, 100 ml and 200 ml LB(+) 
medium containing 100 µg/ml ampicillin were inoculated, respectively, and 
incubated at 37 °C in a shaking incubator overnight. For plasmid DNA extraction, the 
PureLink™ HiPure Plasmid Midiprep or Maxiprep Kit (Invitrogen, Thermo Fisher 
Scientific) was used, respectively. The entire gene of interest was sequenced by 
Eurofins Genomics prior to use. 
3.3.3 Site-Directed Mutagenesis 
For site-directed mutagenesis, primers spanning the site-to-be-mutated in forward 
and reverse direction were commercially obtained (Eurofins Genomics). Both 
primers contained the desired point mutation in the center of their sequence and 
ranged from 29 to 33 bp in size. Next, the complete plasmid was amplified thereby 
incorporating the mutated primer sequence into the novel plasmids. For this 
purpose, the KAPA HiFi HotStart ReadyMix PCR kit (KAPA Biosystems) was used in 
the following pipetting scheme: 
KAPA Quickchange PCR reaction mix  
2x KAPA Hotstart ReadyMix 12.5 µl  
Forward primer (10 µM)  1 µl 
Reverse primer (10 µM)  1 µl 
Template plasmid   10 ng 
H2O     ad 25 µl 




The PCR was run in a ProFlex PCR System Cycler (Applied Biosystems, Thermo 
Fisher Scientific) using the cycling conditions described in Table 5. 
Table 5 KAPA Quickchange PCR cycling conditions 
Step Number of cycles Temperature Duration 
Initial 
Denaturation 
1 95 °C 3 min 
Denaturation 
25 
98 °C 20 s 
Annealing 68 °C 15 s 
Elongation 72 °C 60 s/kb 
Final Elongation 1 72 °C 60 s/kb 
Cooling 1 10 °C 15 min 
 
After successful amplification, the template plasmid was removed by incubating the 
PCR reaction mix with 1 µl FastDigest DpnI (Fermentas, Thermo Fisher Scientific) 
and 2 µl FastDigest buffer in a final volume of 30 µl at 37 °C for 2 h. The enzyme can 
be inactivated afterwards by heating the reaction to 80 °C for 5 min. 5 µl of the 
mixture were transformed into chemically competent bacteria as described in 
chapter 3.3.2. 
3.4 CELL CULTURE AND TRANSFECTION 
3.4.1 HEK293 and HEK293T Cells 
Human embryonic kidney 293 (HEK293) cells (DMSZ) were maintained in DMEM 
medium + GlutaMAX + 1 g/l glucose + pyruvate + 10 % FBS (Biochrom) + 1 % 
penicillin/streptomycin (Biochrom) in a CO2 incubator (Heraeus, Thermo Fisher 
Scientific) at 37 °C and 10 % CO2. The HEK293 derived Lenti-X 293T (HEK293T) 
cells (Clontech, Takara) were cultured in DMEM medium + GlutaMAX + 4.5 g/l 
glucose + 10 % FBS + 1 % penicillin/streptomycin under the same conditions. Both 
cell lines were passaged two times per week at a confluence of approximately 90 %.  
Transient transfections were performed using the calcium phosphate method. For 
this purpose, cells were seeded onto 6 cm cell culture plates. When transfecting 




SpCas9-containing plasmids for western blotting, 10 cm cell culture plates were 
used. The cells were incubated overnight until they reached the desired confluence 
of approximately 70 %. The transfection mix components shown in Table 6 were 
added to a 15 ml Falcon tube in the indicated order. 2x BBS was added dropwise 
during vortexing. 
Table 6 Calcium phosphate transfection mix 
Culture plate diameter 6 cm 10 cm 
DNA 6 µg 10 µg 
H2O ad 270 µl ad 450 µl 
CaCl2 (2.5 M) 30 µl 50 µl 
2x BBS 300 µl 500 µl 
 
The transfection mix was incubated for 3 – 4 minutes at RT and added dropwise to 
the culture medium. The cells were incubated in a 5 % CO2 setting for 3 – 4 h, the 
culture medium was replaced and the cells were maintained at 10 % CO2 for 
approximately 48 h. 
2x BBS solution*   
BES   8.52 g 
NaCl   13.08 g 
Na2HPO4  0.17 g 
H2O   ad 800 ml 
*pH adjusted to 7.080 and filtrated through a 0.2 µm pore size syringe filter (VWR) 
When fluorophore-containing plasmids were transfected, successful transfection 
and expression was evaluated via the EVOS® FL cell imaging system (Life 
Technologies, Thermo Fisher Scientific). 
3.4.2 661W Cells 
The 661W cells were kindly provided by Prof. Muayyad Al-Ubaidi (University of 
Houston). This cell line was cloned from murine retinal tumors and was found to 
exhibit molecular characteristics of cone photoreceptors (al-Ubaidi et al., 1992, Tan 
et al., 2004). 661W cells were maintained in DMEM medium + GlutaMAX + 1 g/l 




glucose + pyruvate + 10 % FBS (Biochrom) + 1 % Antibiotic-Antimycotic in a CO2 
incubator (Heraeus, Thermo Fisher Scientific) at 37 °C and 10 % CO2. They were 
passaged twice per week at a confluence of approximately 90 %. Transient 
transfections were performed using the calcium phosphate method as described in  
3.4.3 Mouse Embryonic Fibroblasts 
Mouse embryonic fibroblasts (MEFs) were generated as described (Jat et al., 1986, 
Xu, 2005). The cells were maintained in DMEM medium + GlutaMAX + 1 g/l glucose 
+ pyruvate + 10 % FBS (Biochrom) + 1 % penicillin/streptomycin (Biochrom) in a 
CO2 incubator (Heraeus, Thermo Fisher Scientific) at 37 °C and 5 % CO2. They were 
passaged once per week at a confluence of approximately 90 %. 
MEFs were transiently transfected using the TurboFectTM Transfection Reagent 
(Thermo Fisher Scientific). Cells were seeded onto a 6 cm cell culture plate and 
incubated until 70 – 90 % confluence was reached. The reaction mix was prepared 
in the following order. 
TurboFectTM transfection mix  
DNA    6 µg 
Serum-free DMEM  ad 600 µl 
TurboFect   12 µl 
After addition of each component, the solution was mixed vigorously by vortexing. 
The transfection mix was incubated for 15 – 20 min at RT and subsequently added 
dropwise to the culture plate. The medium was exchanged after 3 h and the cells 
were harvested 48 h post transfection. When fluorophore-containing plasmids were 
transfected, successful transfection and expression was evaluated via the EVOS® FL 
cell imaging system (Life Technologies, Thermo Fisher Scientific). 
3.5 PRODUCTION OF RECOMBINANT ADENO-ASSOCIATED VIRUSES 
3.5.1 Transfection and Harvest 
Recombinant adeno-associated viruses (rAAVs) were produced by a triple calcium 
phosphate transfection of a pAAV2.1 plasmid containing the gene of interest, a pAD 
Helper plasmid and a plasmid encoding the desired capsid. For subretinal injections 




into the murine retina, the 2/8Y733F capsid variant was selected due to its high 
efficiency in transducing photoreceptors and the RPE (Petrs-Silva et al., 2009). 
HEK293T cells were seeded onto 15x 15 cm cell culture plates and incubated over 
night until a confluence of 60 – 80 % was reached. Prior to transfection, the FBS-
containing medium was replaced by serum-free medium. The transfection reagents 
were added to a 50 ml Falcon tube in the indicated order. CaCl2 and 2x BBS were 
added dropwise during vortexing. 
Transfection mix for AAV production 
pAAV2.1 plasmid  270 µg 
pAD Helper plasmid  X µg 
Capsid plasmid  Y µg 
H2O    ad 11.85 ml 
Polybrene (8 mg/ml) 15 µl 
Dextran (10 mg/ml)  1.5 ml 
CaCl2 (2.5 M)   1.5 ml 
2x BBS   15 ml  
The required amounts of pAD Helper and capsid plasmid were calculated using the 
following formulas: 
X µg =
270 µg × MM of pAD Helper
MM of pAAV2.1
 
Y µg =  
270 µg × MM of capsid plasmid 
MM of pAAV2.1
 
2 ml of the transfection mix were added dropwise to each of the 15 culture plates. 
The plates were rocked gently and subsequently placed in a 5 % CO2 setting for 24 
h. The medium was exchanged afterwards and the plates were placed in a 10 % CO2 
setting for another 48 h. 
The virus-containing culture medium was harvested twice. The first harvest took 
place 72 h post transfection by collecting the entire medium of all plates and adding 
fresh medium. The second harvest took place after another 72 h incubation period. 
The culture medium was collected into a 500 ml centrifugation tube. The residual 
cells were removed from the medium by centrifugation at 4,000 rpm and 4 °C for 15 




min (JA-10 rotor, J2-MC High speed centrifuge, Beckman Coulter) and filtration of 
the supernatant through a 0.45 µm PES filter unit (Nalgene, Thermo Fisher 
Scientific). A 40 % polyethylene glycol (PEG) solution was added to the flow-through 
to a final concentration of 8 % and kept at 4 °C overnight to precipitate the viral 
particles. Subsequently, the solution was centrifuged at 4,000 rpm and 4 °C for 15 
min (JA-10 rotor, J2-MC High speed centrifuge, Beckman Coulter). The supernatant 
was discarded and the virus-containing pellet was stored at -20 °C until further 
processing. 
3.5.2 Iodixanol Density Gradient Centrifugation 
The pellet was re-suspended in 7.5 ml sterilely filtrated PBS and incubated with 
Benzonase® (VWR) at a final concentration of 50 U/ml in a water bath (Haake) at 
37 °C for 30 min to remove residual, non-packaged DNA. Next, the virus suspension 
was pipetted into a Quick-Seal polypropylene tube (39 ml, Beckman Coulter) and a 
density gradient was established by adding solutions with different iodixanol 
concentrations below the virus suspension in the following order: 7 ml of 15 %, 6 
ml of 25 %, 5 ml of 40 % and 6 ml of 60 % iodixanol solution. For this purpose, the 
MINIPULS 3 peristaltic pump (Gilson) and a long glass pipette were used. 
Subsequently, the tubes were sealed with the Beckman Tube Topper and 
centrifuged at 70,000 rpm and 18 °C for 1 h 45 min in an Optima L-80K 
ultracentrifuge (70 Ti rotor, Beckman Coulter). Afterwards, the top of the tube was 
perforated with a cannula to ensure air flow. The 40 % iodixanol phase enriched 
with viral particles was collected from the gradient using a 20 G cannula and 20 ml 
syringe by puncturing the tube laterally at the border between the 40 % and the 60 
% phase. The virus-containing solution was stored at -80 °C until further processing. 
15 % iodixanol solution*   25 % iodixanol solution*   
10x PBS   5 ml  10x PBS   5 ml 
MgCl2 (1 M)   50 µl  MgCl2 (1 M)   50 µl 
KCl (2.5 M)   50 µl  KCl (2.5 M)   50 µl 
NaCl (5 M)   10 ml  OptiprepTM (Progen) 20.9 ml 
OptiprepTM (Progen) 10 ml  phenol red (1 %, w/v) 50 µl 
phenol red (1 %, w/v) 37.5 µl H2O    ad 50 ml 
H2O    ad 50 ml 




40 % iodixanol solution*   60 % iodixanol solution*   
10x PBS   5 ml  MgCl2 (1 M)   50 µl 
MgCl2 (1 M)   50 µl  KCl (2.5 M)   50 µl 
KCl (2.5 M)   50 µl  OptiprepTM (Progen) 50 ml 
NaCl (5 M)   10 ml  phenol red (1 %, w/v)  35.5 µl 
OptiprepTM (Progen) 33.3 ml   
H2O    ad 50 ml 
*filtrated through a 0.2 µm pore size syringe filter (VWR) 
3.5.3 Anion Exchange Chromatography 
To further purify the virus, an anion exchange chromatography was performed 
employing the ÄKTAprime plus chromatography system (GE Healthcare), the 5 ml 
HiTrapTM Q FF anion exchange chromatography column (GE Healthcare) and the 
PrimeView 5.31 software (GE Healthcare). Before starting, the column was 
equilibrated with buffer A and the virus-containing solution was diluted with this 
buffer in a 1:1 ratio. The solution was loaded onto the column via a loop injector (50 
ml Superloop, GE Healthcare). The UV light-absorbance and conductance properties 
of the collected fractions were monitored providing information about the amount 
of contained virus. Remaining bound molecules were removed from the column 
using a 2.5 M NaCl solution. All virus-containing fractions were pooled and used for 
subsequent processing. 
Buffer A *   
Tris  20 mM 
NaCl  15 mM 
H2O  ad 500 ml 
*pH adjusted to 8.5 
3.5.4 Increase of rAAV Concentration 
To increase the virus concentration, Amicon® Ultra-4 centrifugation filter units 
(Merck) with a molecular weight cut-off of 100 kDa were used. The virus-containing 
solution was loaded on top of the filter unit and centrifuged at 4,000 rpm (JA-10 
rotor, J2-MC High speed centrifuge, Beckman Coulter) and 4 °C in 20 min intervals 
until the volume was reduced to 500 µl. Subsequently, the filter unit was washed 




with 1 ml 0.014 % Tween/PBS-MK. The solution was further centrifuged under the 
same conditions until the volume was reduced to 100 µl of concentrated viral 
solution. 10 µl aliquots were prepared and stored at -80 °C until use. 
0.014 % Tween/PBS-MK solution  
10x PBS   50 ml 
MgCl2 (1 M)   500 µl 
KCl (2.5 M)   500 µl 
Tween-20   70 µl  
H2O    ad 500 ml 
3.5.5 rAAV Titer Determination 
To determine the titer of the produced rAAVs, a qPCR was performed using the 
StepOnePlus Real-Time PCR system (Applied Biosystems, Thermo Fisher Scientific). 
A standard curve was produced to serve as a reference. For this purpose, a fragment 
containing a part of the ITR was amplified by PCR using the following primers. 
ITR2 forward: 5’ GGAACCCCTAGTGATGGAGTT 3’ 
ITR2 reverse: 5’ CGGCCTCAGTGAGCGA 3’ 
Next, the amplicon was purified and the concentration was determined using the 
NanodropTM 2000c spectrophotometer (Thermo Fisher Scientific). To obtain a 
standard solution containing 1010 copies of the amplicon in 5 µl, the following 




] =  
1010  × 660 × 1012
pg
mol
 × ITR fragment size
6.022 × 1023  
1
mol
×  5 µl
 
After preparation of a standard solution with concentration c, a dilution series 
ranging from 1010 to 101 copies was made. To attain the standard curve, a qPCR was 
run with three technical replicates of the standard dilution series. For this purpose, 
a MicroAmp™ Fast Optical 96-Well Reaction Plate (Applied Biosystems, Thermo 
Fisher Scientific) and the PowerUpTM SYBRTM Green Master Mix (Thermo Fisher 
Scientific) were used. The virus solution was diluted 100-fold in H2O and run on the 




same reaction plate with three technical replicates. The reaction mix was prepared 
as follows. 
qPCR reaction mix    
PowerUpTM Master Mix 10 µl 
ITR2 F primer (10 µM) 0.6 µl 
ITR2 R primer (10 µM) 0.6 µl 
Virus or standard  5 µl 
H2O    ad 20 µl 
The qPCR was run using the program depicted in Table 7. 
Table 7 Fast cycling program for real-time qPCR 
Step Number of 
cycles 
Temperature Duration 
Uracil DNA glycosylase 
activation 
1 50 °C 2 min 
Dual-LockTM DNA 
polymerase activation 
1 95 °C 2 min 
Denaturation 
40 
95 °C 5 s 
Annealing 58 °C 5 s 
Extension 60 °C 30 s 
Melt curve acquisition 
1 95 °C 15 s 
1 60 °C 1 min 
1 
Ramp to 95 °C 
(0.3 °C/s) 
2 min 
1 95 °C 15 s 
 
The obtained data was analyzed using the StepOnePlus Real-Time PCR system 
software (Applied Biosystems, Thermo Fisher Scientific). Baseline settings and 
cycling threshold position were adjusted manually if necessary. The standard curve 
was attained by plotting the resulting cycle threshold (Ct) values against the 
logarithm of the dilution. The number of viral genomes per µl (vg/µl) of the 
produced rAAVs could be inferred from the standard curve. 





All animal protocols were performed with permission of local authorities (District 
Government of Upper Bavaria) and in accordance with the German laws on animal 
welfare (Tierschutzgesetz). For all experiments, C57Bl6/J mice were used. The mice 
were maintained at a 12 h light/dark cycle and received food and water ad libitum.  
3.7 SUBRETINAL INJECTION 
For subretinal injections, C57Bl6/J mice at postnatal day 21 (P21) were 
anesthetized by an intraperitoneal injection of ketamine (40 mg/kg body weight) 
and xylazine (20 mg/kg body weight). After a complete absence of the paw 
withdrawal reflex the pupils were dilated by administration of atropine (1 %)- and 
tropicamide (0.5 %)-containing eye drops (Mydriaticum Stulln, Pharma Stulln 
GmbH). The fundus of the eye was focused using a surgical microscope (OPMI 1 FR 
pro, Zeiss). 1 µl containing 1010 rAAV particles was injected subretinally by a single 
injection with a NANOFIL 10 µl syringe (World Precision Instruments) and a 34 G 
beveled needle (World Precision Instruments). The injected eyes were treated with 
an eye ointment containing 5 mg/g gentamicin and 0.3 mg/g dexamethasone. The 
mice were kept on a heating plate (Leica HI1120, Leica Biosystems) at 37 °C until 
full recovery from anesthesia. Two to four weeks post-injection, all injected retinas 
were harvested and processed for RT-PCR analysis or immunohistochemistry.  
3.8 IMMUNOHISTOCHEMISTRY 
Subretinally injected mice were euthanized via cervical dislocation. The eyes were 
removed and placed in 0.1 M phosphate buffer (PB). Subsequently, the eyeball was 
punctured at the ora serrata with a 21 G cannula and fixed in 4 % paraformaldehyde 
(PFA, Sigma Aldrich, pH adjusted to 7.4) for 5 min. Next, the eye was positioned 
below a stereomicroscope (Stemi 2000, Zeiss) on a filter paper drenched with 0.1 M 
PB. By cutting alongside the ora serrata using surgical scissors (SuperFine Vannas, 
World Precision Instruments), the cornea, lens and vitreous body were removed. 
The remaining part of the eyeball containing the retina was fixed in 4 % PFA for 45 
min at RT and subsequently washed 3 times for 5 min in 0.1 M PB. For 




cryopreservation, the eyeball was placed in a 30 % sucrose solution (w/v) overnight 
at 4 °C.  
The next day, the eyeball was embedded in tissue freezing medium (Sakura) and 
chilled on dry ice until the medium solidified. The retina was sectioned using a 
cryostat (Leica CM3050 S, Leica Biosystems) into 10 µm thick slices, collected on 
coated glass object slides (Superfrost Plus microscopic slides, Thermo Fisher 
Scientific) and stored at -20 °C. 
For immunohistochemical staining, the retinal sections were thawed at RT and 
encircled using a Super PAP Pen Liquid Blocker (Science Services). Subsequently, 
the sections were rehydrated with 0.1 M PB for 5 min and fixed with 4 % PFA for 10 
min. After washing the sections three times for 5 min each with 0.1 M PB, a solution 
containing the primary antibodies, 5 % ChemiBLOCKER (Merck) and 0.3 % Triton 
X-100 in 0.1 M PB was applied. The cryosections were incubated with the primary 
antibody solution overnight at 4 °C. The next day, the retinas were washed three 
times with 0.1 M PB for 5 min and incubated with a solution containing the 
secondary antibodies and 2 % ChemiBLOCKER in 0.1 M PB for 1.5 h at RT. After 
subsequent washing with 0.1 M PB three times for 5 min, the cell nuclei were stained 
with 5 µg/ml Hoechst 33342 solution (Invitrogen). Finally, the sections were 
washed with 0.1 M PB, embedded in Fluoromount-G Mounting Medium (Thermo 
Fisher Scientific), covered by a cover slip and stored at 4 °C. All antibodies used for 
immunohistochemistry are listed in Table 8. 
0.1 M phosphate buffer (PB)* 
Na2HPO4 x 2H2O 28.48 g 
NaHPO4 x H2O 5.52 g 
H2O   ad 2 l 
*pH adjusted to 7.4 
Table 8 List of all antibodies used for immunohistochemistry 
Antibody Source Catalog nr. Dilution 
Myc-Tag (9B11) Mouse mAb Cell Signaling 
Technology 
2276 1:200 
α-CNGB1a-antibody, rabbit in lab production  – 1:10,000 




(Huttl et al., 2005) 
Cy™5 AffiniPure Goat Anti-














3.9 CONFOCAL MICROSCOPY 
Images of the stained retinas were obtained using a Leica TCS SP8 inverted confocal 
laser scanning microscope (Leica Microsystems) equipped with a 405 nm diode as 
well as a 552 nm and a 633 nm optically pumped semiconductor laser appropriate 
for the excitation of Hoechst 33342, Cy3 and Cy5, respectively. The filter settings 
were chosen according to the emission spectrum of the respective dye. Images were 
acquired as z-stacks (1 µm steps) with a HC PL APO 40x/1.30 Oil CS2 objective (Leica 
Microsystems) and type F immersion liquid (Leica Microsystems) using the LAS X 
software (Leica Microsystems). With the same software, z-stacks were condensed 
into 2D images by applying a maximum intensity projection. The images were 
processed further with the ImageJ 1.48v software (National Institutes of Health). 
Images of transiently transfected living cells were obtained using the Leica TCS SP8 
spectral confocal laser scanning microscope (Leica Microsystems) equipped with a 
448 nm, a 514 nm and a 552 nm optically pumped semiconductor laser appropriate 
for the excitation of cerulean, citrine and mCherry, respectively. The filter settings 
were chosen according to the emission spectrum of the respective fluorophore. 
Images were acquired with a HCX APO 20x/1.00 W objective (Leica Microsystems). 
All images were processed with the ImageJ 1.48v software. 
3.10 RNA EXTRACTION 
For RNA extraction from injected retinas, the mice were euthanized via cervical 
dislocation. The retinas were collected by placing blunt forceps below the eye, 
incising the eye ball using a sterile scalpel (Swann-Morton) and gradually moving 
the forceps upward. Three retinas were pooled per construct and RNA was 
extracted using the RNeasy Mini Kit (Qiagen) according to the manufacturer’s 




instructions. For disruption, the tissue was homogenized by adding 350 µl of RLT 
buffer (Qiagen, provided with the kit) + 3.5 µl β-mercaptoethanol (β-ME, Sigma 
Aldrich) and passing it through a 20 G needle fitted onto a sterile syringe at least five 
times. The remaining steps were executed according to protocol. The RNA was 
eluted in 30 µl RNAse-free H2O.  
For RNA extraction from transiently transfected cells, the RNeasy Mini Kit Plus 
(Qiagen) was used. For this purpose, the medium was removed from the 6 cm 
culture plates and the cells were scrapped off using a 16 cm cell scraper (Sarstedt). 
The cells were collected in 500 µl medium into a 2 ml safe-lock tube (Eppendorf) 
and centrifuged at 3,000 x g and 4 °C for 10 min. The supernatant was discarded and 
the pellet was re-suspended in 600 µl RLT Plus buffer (Qiagen, provided with the 
kit) + 6 µl β-ME (Sigma Aldrich). A steel ball was placed into each tube and the cells 
were disrupted using the mixer mill MM400 (Retsch) at 30 Hz for 1 min. Afterwards, 
the balls were removed and the suspension was centrifuged at 21,000 x g and RT for 
5 min. The remaining steps were executed according to protocol including an 
optional step removing the genomic DNA via gDNA eliminator spin columns. The 
RNA was eluted in 30 µl RNAse-free H2O. 
The RNA concentrations were measured using the NanodropTM 2000c 
spectrophotometer (Thermo Fisher Scientific). The RNA was kept on ice until 
further use or stored at -20 °C for short-term or -80 °C for long-term storage. 
3.11 cDNA SYNTHESIS 
For cDNA synthesis, the Revert Aid First Strand cDNA Synthesis Kit (Thermo Fisher 
Scientific) was used according to the manufacturer’s instructions. Equal amounts of 
RNA were used per experiment. 
cDNA synthesis reaction mix     
Total RNA     up to 2 µg 
Oligo (dT)18 primer    1 µl 
Random hexamer primer   1 µl 
Nuclease-free H2O    ad 12 µl 




The reaction mix was incubated at 65 °C for 5 min to remove secondary structures 
of the RNA and subsequently chilled to 10 °C. Afterwards, the following components 
were added. 
5x Reaction buffer    4 µl 
RiboLock RNase Inhibitor (20 U/µl) 1 µl 
dNTP mix (10 mM)    2 µl 
RevertAid M-MuLV RT (200 U/μl)  1 µl 
The cDNA reaction mix was incubated in a Mastercycler® nexus gradient 
(Eppendorf) using the following cycling conditions. 
cDNA synthesis cycling conditions 
25 °C  5 min 
42 °C  60 min 
70 °C  5 min 
10 °C  ∞ 
The cDNA was kept on ice until further use or stored at -20 °C for short-term or -80 
°C for long-term storage. 
3.12 REVERSE TRANSCRIPTION PCR 
Reverse transcription PCR (RT-PCR) was performed using the Herculase II fusion 
DNA polymerase (Agilent Technologies) or the VWR Taq DNA polymerase (VWR) by 
following the respective protocol. 
Herculase II RT-PCR reaction mix    
5x Herculase II Reaction Buffer 5 µl    
dNTPs (10 mM)   1 µl   
Forward primer (10 µM)  1 µl   
Reverse primer (10 µM)  1 µl   
Herculase II DNA polymerase 0.5 µl   
cDNA     1 µl   
H2O     ad 25 µl  
 




VWR Taq RT-PCR reaction mix   
10x Key Buffer   2.5 µl  
dNTPs (10 mM)   1 µl 
Forward primer (10 µM)  1 µl  
Reverse primer (10 µM)  1 µl 
Taq DNA polymerase (5 U/µl) 0.25 µl  
cDNA     1 µl  
H2O     ad 25 µl 
A list of all RT-PCR primers used in this study can be found in 7.1. The RT-PCR was 
run in a ProFlex PCR System Cycler (Applied Biosystems, Thermo Fisher Scientific) 
using the respective cycling conditions described in Table 9 and Table 10. 
Table 9 Herculase II RT-PCR cylcling conditions 
Step Number of cycles Temperature Duration 
Initial 
Denaturation 
1 95 °C 2 min 
Denaturation 
15 - 35 
95 °C 20 s 
Annealing 50 °C – 72 °C 30 s 
Elongation 72 °C 60 s/kb 
Final Elongation 1 72 °C 4 min 
Cooling 1 10 °C 15 min 
 
Table 10 VWR Taq polymerase RT-PCR cycling conditions 
Step Number of cycles Temperature Duration 
Initial 
Denaturation 
1 95 °C 2 min 
Denaturation 
25 - 35 
95 °C 30 s 
Annealing 48 °C – 65 °C 40 s 
Elongation 72 °C 60 s/kb 
Final Elongation 1 72 °C 5 min 
Cooling 1 10 °C 15 min 
 




The RT-PCR products were separated on a 0.7-2 % agarose gel and detected with 
the ChemiDocTM MP Imaging System (Bio-Rad). The sequence identity of all bands 
was confirmed by sequencing (Eurofins Genomics). 
3.13 BRANCH POINT ANALYSIS 
3.13.1 Nested Lariat RT-PCR 
RNA was extracted according to the protocol described in 3.10. 10 µg RNA were 
incubated with RNase R (Lucigen) following the manufacturer’s instructions to 
remove any non-circular RNA. Subsequent cDNA synthesis (Revert Aid First Strand 
cDNA Sythesis Kit, Life Technologies) was performed as described in 3.11. For this 
reaction, only the random hexamer primer was used. Next, the lariats were 
amplified via a nested RT-PCR using the Herculase II fusion DNA polymerase 
(Agilent Technologies). For the first round of amplification, the reaction mix was 
prepared as described in 3.12. For the second round of amplification, 5 µl of the first 
PCR were added to the reaction mix instead of the cDNA. Moreover, a second primer 
pair binding 25 – 30 bp downstream of the first primer pair was used. The applied 
cycling conditions are listed in Table 11. 
Table 11 Herculase II nested lariat PCR cycling conditions 
Step Number of cycles Temperature Duration 
Initial 
Denaturation 
1 95 °C 2 min 
Denaturation 
35 
95 °C 20 s 
Annealing 65 °C 30 s 
Elongation 72 °C 40 s 
Final Elongation 1 72 °C 4 min 
Cooling 1 10 °C 15 min 
 
The nested RT-PCR products were analyzed on a 2 % agarose gel. Obtained bands 
were excised and the DNA was extracted using the Qiaquick Gel Extraction kit 
(Qiagen) according to the manufacturer’s instructions. 




3.13.2 TOPO Cloning and Analysis of Lariats 
To be able to analyze the sequence identity of the single lariats, the products of the 
nested RT-PCR were subcloned into plasmids. For this purpose, 3’-adenine 
overhangs were added to the DNA fragments post amplification by incubating one 
unit of Taq Polymerase (VWR) with the PCR reaction for 10 min at 72 °C. 
Subsequently, the lariats were subcloned into a TOPO vector (TOPO TA Cloning Kit, 
Thermo Fisher Scientific) according to the manufacturer’s instructions. The 
plasmids were transformed into bacteria and a small-scale plasmid preparation was 
performed as described in 3.3.2. The resulting plasmids were sequenced (Eurofins 
Genomics) and the obtained lariat sequences were analyzed by alignment with the 
investigated intron using the DNAMAN software (Lynnon Biosoft). 
3.14 PROTEIN EXTRACTION 
For protein extraction, the medium was removed from the 6 or 10 cm culture plates. 
The cells were scrapped off using a 16 cm cell scraper (Sarstedt) and collected in 
500 µl medium into a 2 ml safe-lock tube (Eppendorf). The cell suspension was 
centrifuged at 3,000 x g and 4 °C for 10 min, the supernatant was discarded and the 
pellet re-suspended in 150 µl and 250 µl Triton X-100 (TX) lysis buffer for 6 cm and 
10 cm plates, respectively. A steel ball was added to each safe-lock tube and the cells 
were disrupted using the mixer mill MM400 (Retsch) at 15 Hz for 30 s. Afterwards, 
the tubes containing the balls were rotated end-over-end (VWRTM tube rotator) for 
20 min at 4°C. Subsequently, the balls were removed and the lysates were 
centrifuged at 5,000 x g for 10 min at 4 °C. The protein-containing supernatant was 
transferred into a new reaction tube and stored at -20 °C. 
Triton X-100 lysis buffer*  
Triton X-100  2.5 ml 
NaCl (5 M)  15 ml 
CaCl2 (2.5 M)  0.4 ml 
H2O   ad 500 ml 
*cOmpleteTM ULTRA Protease Inhibitor Cocktail tablets (Roche) were added right 
before use (1 tablet/10 ml)  




Total protein concentration was determined using the Bradford assay (Bradford, 
1976). 5 µl of the protein lysate were mixed with 95 µl of a 0.15 M NaCl solution and 
transferred into a PMMA standard disposable cuvette (BRAND). Subsequently, 1 ml 
of Coomassie blue solution was added, thoroughly mixed by pipetting and incubated 
at RT for 2 min. Using the BioPhotometer (Eppendorf), the absorption of the solution 
was measured against a blank control containing 5 µl of the TX lysis buffer. The 
obtained value represents the total amount of protein contained in 5 µl lysate. 
Coomassie blue solution    
Coomassie brilliant blue G250 50 mg 
95 % ethanol (v/v)   25 ml 
85 % phosphoric acid (v/v) 50 ml 
H2O     ad 500 ml 
3.15 WESTERN BLOTTING 
For western blotting, 10 – 35 µg protein were mixed with 6x Laemmli + DTT buffer 
and incubated at 72 °C for 10 min. Equal amounts of protein were used for each 
experiment. For SDS-PAGE, polyacrylamide running gels were prepared using the 
Mini-Protean 3 gel system (Bio-Rad).  For the detection of small proteins (up to 35 
kDa) a 15 % gel was used, while a 6 % gel was prepared for the detection of larger 
proteins. After solidification of the running gel, a stacking gel was added on top. 
4x Tris-HCl/SDS pH 6.8 buffer*  4x Tris-HCl/SDS pH 8.8 buffer* 
Tris-HCl  0.5 M   Tris-HCl  1.5 M 
SDS   0.4 % (w/v)  SDS   0.4 % (w/v) 
*pH adjusted to 6.8    *pH adjusted to 8.8 
6x Laemmli + DTT buffer    
4x Tris-HCl/SDS pH 6.8 buffer 7 ml 
Glycerol    3 ml 
SDS     1 g 
Bromophenol blue   1.2 mg 
DTT     0.93 g 
 




Running gel for SDS-PAGE  6 %  15 %  
30 % acrylamide/bis-acrylamide 2.3 ml  5.75 ml 
4x Tris-HCl/SDS pH 8.8 buffer  2.8 ml  2.8 ml 
H2O     6.2 ml  2.75 ml 
APS     22.5 µl 22.5 µl 
TEMED*    7.5 µl  7.5 µl 
*added right before pouring of gel 
Stacking gel for SDS-PAGE    
30 % acrylamide/bis-acrylamide 0.5 ml 
4x Tris-HCl/SDS pH 6.8 buffer  0.95 ml  
H2O     2.3 ml  
APS     18.75 µl 
TEMED*    3.75 µl 
*added right before pouring of gel 
The lysates and a PageRulerTM Plus Prestained Protein Ladder (Thermo Fisher 
Scientific) were loaded onto the gel and the SDS-PAGE was run at 140 V and RT for 
1 h 10 min in 1x electrophoresis buffer. 
10x electrophoresis buffer  
Tris   30 g 
Glycine  144 g 
SDS   10 g 
H2O   ad 1 l 
Subsequently, the separated proteins were transferred onto a PVDF membrane 
(PEQLAB, VWR) using a Mini Trans-Blot cell (Bio-Rad). Western blotting was 
performed at 100 V and RT for 1 h 30 min in 1x blotting buffer. Afterwards, the 
membrane was transferred into a blocking solution containing 5 % non-fat dried 
milk powder (w/v, AppliChem) in TBST buffer and incubated for 1 h at RT. Next, the 
membrane was incubated in a solution containing the primary antibody and 1 % 
non-fat dried milk powder (w/v, AppliChem) in 5 ml TBST buffer for 1 h at RT or 
overnight at 4 °C. After three subsequent washing steps in TBST buffer for 5 min 
each, the membrane was incubated in a solution containing the secondary antibody 




and 1 % non-fat dried milk powder (w/v, AppliChem) in 5 ml TBST buffer for 1 h at 
RT. After washing the membrane three more times in TBST buffer for 5 min each 
and rinsing it with H2O, the western blot was developed by applying Western 
Blotting Luminol Reagent (Santa Cruz) according to the manufacturer’s instructions. 
The signal was detected using the ChemiDocTM MP Imaging System (Bio-Rad). All 
antibodies used for western blotting can be found in Table 12. 
10x blotting buffer    TBST buffer    
Tris   30 g   Tris   1.2 g 
Glycine  144 g   NaCl   8.0 g 
H2O   ad 1 l   Tween-20  1 ml 
      H2O   ad 1 l 
Table 12 List of all antibodies used for western blotting 
Antibody Source Catalog nr. Dilution 
Living Colors A.v. 
Monoclonal Antibody (JL-
8), mouse α-GFP 








Diagenode C15310258 1:1,000 
goat anti-mouse IgG-HRP Santa Cruz 
Biotechnology 
sc-2005 1:2,000 




For quantification, the Image Lab software (Bio-Rad) was used. Bands were 
automatically detected by the software and adjusted manually. The total volume 
intensity values obtained for the detected bands were transferred into an Excel file 
(Microsoft). All band intensities were normalized to the intensities obtained for the 
beta tubulin band for loading control. The relative amount of reconstitution was 




calculated with respect to the cis-splicing control, which represents 100 % 
efficiency. 
3.16 STATISTICS 
The GraphPad Prism software 5 was used for scientific graphing and statistical 
analysis. The corresponding number of independent samples (n), applied statistical 
tests and significance levels are indicated for each experiment in the respective 






4.1 INVESTIGATION OF TWO ADRP-CAUSING RHODOPSIN 
MUTATIONS AND THEIR EFFECT ON MRNA SPLICING 
4.1.1 Generation of De Novo Splice Acceptor Site in RHO Exon 3 by c.620T>G 
Mutation 
Patients carrying the c.620T>G and c.620T>A mutations in RHO show a strikingly 
different disease penetrance. c.620T>G leads to an early onset and severe form of 
RP, while patients affected by the c.620T>A mutation show a late onset and a mild 
disease phenotype. These mutations are both located in RHO exon 3, which encodes 
for transmembrane helix domain 5 (H5) and the major part of the second 
extracellular loop (EL2) (Figure 3A). Both mutations affect the second nucleotide of 
the triplet encoding the methionine residue at position 207 (Met207), which is 
involved in binding of 11-cis-retinal (Figure 3B). Furthermore, both mutations are 
classified as missense mutations expected to replace Met207 with a positively 
charged amino acid, i.e. Met207Arg and Met207Lys. However, recent studies 
investigating mutations affecting Met207 could only detect moderate impact on 11-
cis-retinal binding (Aguila et al., 2009, Audo et al., 2010a, Piechnick et al., 2012, 
Hernandez-Rodriguez et al., 2013) suggesting that the difference in disease course 
most likely does not result from differential impact on ligand binding. Another 
plausible explanation for these puzzling disease courses might be that they arise 
from a differential impact of these two mutations on mRNA splicing. 
To address this issue, an in silico prediction analysis has been performed. Indeed, 
c.620T>G was predicted by two independent splicing prediction software tools 
(NNSplice and Human Splicing Finder, HSF) to generate a novel splice donor or 
acceptor site (Figure 9A, B). By contrast, c.620T>A was not predicted to alter mRNA 
splicing. To validate this finding experimentally, HEK293 cells have been transiently 
transfected with RHO minigenes containing all native exons and most native intronic 
regions of the human rhodopsin gene (Figure 10A, B). When analyzing mRNA 
splicing via RT-PCR, correctly spliced transcript could only be identified for the wild 






Figure 9 Splice acceptor site elements in WT and mutant RHO exon 3 
A, Schematic illustration of all elements necessary to form a mammalian functional 
unit of a splice acceptor site (SAS). BP, branch point; PPT, polypyrimidine tract. B, 
Sequences of wild type (WT), c.620T>G and c.620T>A RHO exon 3 (brown 
uppercase) and partial intronic sequences (black lowercase). The point mutations 
are highlighted in red. The potential PPTs and SASs matching the consensus 
sequences are depicted with brown and pink rectangles, respectively. C, 





showing the exon 2-exon 3 junction. D, Deletion of 90 bp in the c.620T>G mRNA 
causes an in-frame deletion of the 30 aa forming EL2 and the first 5 aa of H5 
(shadowed area). 
By contrast, the c.620T>G mutation resulted in two aberrantly spliced mRNAs 
originating from usage of a novel splice acceptor site (SAS) in exon 3 generated by 
the point mutation (Figure 10C). This aberrant splicing leads to an in-frame deletion 
of the 90 bp encoding the main part of EL2 and the first 5 aa of H5 (Figure 9C, D). 
4.1.2 Mislocalization of c.620T>G Minigene-Born Protein in Vitro 
As a next step, the expression pattern of the RHO minigene-born protein was 
investigated in transfected HEK293 cells. In heterologous expression systems, 
rhodopsin is usually located in the cell membrane (Liu et al., 2013, McKeone et al., 
2014). In line with this, a substantial portion of the WT rhodopsin was detected as a 
small layer surrounding the cells, most likely representing the plasma membrane 
(Figure 10D). The expression pattern of the c.620T>A mutant protein was not 
distinguishable from the one observed for the WT rhodopsin. However, the 
c.620T>G mutant protein was completely absent from the cell membrane and 
mainly found in the cytosol (Figure 10D). 
 
Figure 10 Generation of a de novo splice acceptor site in RHO exon 3 by 
c.620T>G 
A, Structure of human rhodopsin gene (RHO). Exons are depicted as beige boxes. 
Start and stop codon are marked as traffic lights. B, RHO minigene used for in vitro 
studies. The minigene consists of all native exons and most native intronic 
sequences and is expressed under a cytomegalovirus (CMV) promoter. Citrine was 





vectors for subsequent analysis in vivo, intron 1 was shortened as indicated. Primers 
used for RT-PCR (C) are indicated as black arrows. C, RT-PCR from HEK293 cells 
transiently transfected with the wild type (WT), c.620T>A or c.620T>G minigene. 
The most prominent bands are indicated by an arrow. An additional faint band 
representing aberrantly spliced mRNA with an intron 3 retention is highlighted by 
an asterisk. The sequence identity determined by sequencing is depicted in the right 
panel. D, Confocal live images of transfected HEK293 cells. Scale bar, 10 µm. 
In the RT-PCR assay, no correctly spliced RHO mRNA could be detected for the 
c.620T>G mutant. Nevertheless, this experiment is not sensitive enough to exclude 
that some residual protein originating from correctly spliced transcript below the 
detection limit might be present. This issue is particularly important, as a gain-of-
function or dominant-negative effect of the resulting Met207Arg protein could be 
contributing to the severe disease phenotype. The live imaging experiment shown 
in Figure 10D is in principle expected to be sensitive enough for the detection of 
proteins expressed at low levels. However, this experimental setup does not allow 
for discrimination between protein expressed from aberrantly or from correctly 
spliced mRNA.  
 
Figure 11 Live imaging dual fluorescence splicing detection assay 
A, Modified RHO minigenes (WTmod and c.620T>Gmod) containing a citrine sequence 
5’ of exon 1 as an expression control and a mCherry sequence 3’ of exon 5 as a 





the minigenes resulting in an aa exchange (Arg177Gly) upon correct splicing or a 1 
bp frameshift and a premature stop codon in exon 3 upon aberrant splicing at the 
c.620T>G SAS. Changed amino acids are shown in blue. B, Left panel, Schematic 
depiction of differentially spliced mRNAs expressed from WTmod or c.620T>Gmod 
minigenes. Right panel, Confocal live images of HEK293 cells transfected with the 
modified minigenes. Aberrant splicing results in an absence of mCherry 
fluorescence. Scale bar, 10 µm. 
To enable a fluorescence-based discrimination of proteins expressed from these two 
splice isoforms, I developed a live imaging dual fluorescence splicing detection assay 
(Figure 11). Using this assay, a robust signal originating from protein expressed 
from aberrantly spliced c.620T>G transcript could be detected. However, there was 
no detectable signal corresponding to minigene-born Met207Arg protein expressed 
from correctly spliced transcript. These data are indicating that the novel SAS 
generated by the c.620T>G mutation is used exclusively and that the Met207Arg 
protein most likely does not naturally exist. 
4.1.3 Missplicing and Mislocalization of the c.620T>G Mutant in Mouse 
Photoreceptors 
mRNA splicing can vary in a cell type-specific manner (Arias et al., 2010). Therefore, 
the results obtained from HEK293 cells might not reflect the native situation in rod 
photoreceptors. To investigate this issue, RHO WT or mutant minigenes were 
delivered subretinally into mouse retinas via recombinant adeno-associated virus 
(rAAV)-mediated gene transfer and expressed in rod photoreceptors using a murine 
rhodopsin promoter (Figure 12A). The RT-PCR results obtained from these retinas 
were very similar to those from the in vitro experiments shown in Figure 10C. 
However, the faint band corresponding to aberrantly spliced mRNA with an intron 
3 retention found in HEK293 cells (cf. Figure 10C) was not detected in vivo (Figure 
12B). Next, the WT and mutant protein expression was investigated in transduced 
murine rod photoreceptors. As expected, minigene-born WT rhodopsin was found 
in the rod outer segments. The expression of c.620T>A mutant protein was virtually 
indistinguishable from the WT one suggesting no substantial effects of this mutant 






Figure 12 RHO minigene expression in mouse rod photoreceptors 
A, Structure of RHO minigenes used for in vivo expression. Gene expression was 





detection. The minigene was utilized for simultaneous analysis of mRNA splicing 
and protein expression. Primers used for RT-PCR are indicated as black arrows. ITR, 
inverted terminal repeats. pA, polyadenylation signal. B, Left panel, RT-PCR from 
retinas isolated four weeks post-injection from C57Bl/6J mice. Right panel, 
sequence identity of the detected bands determined by sequencing. C, Confocal 
images of immunostained retinal slices harvested four weeks post-injection. 
Minigene-born protein was detected using an anti-myc antibody. The anti-CNGB1a 
antibody was used as a rod outer segment marker. Cell nuclei were stained with 
Hoechst. Dashed rectangles mark the areas magnified in the right panel. Scale bar, 
10 µm. 
However, the c.620T>G mutant protein was not detectable in the outer segments 
but was mainly localized in the inner segments of the photoreceptors with some 
weak signal in the cell soma (Figure 12C). Collectively, these findings demonstrate 
that c.620T>G, in contrast to c.620T>A, is a splicing mutation which leads to a 
truncated and mislocalized protein in vitro and in vivo. 
4.1.4 Identification of Core Element Underlying the c.620T>G SAS Strength 
Both, the in vitro as well as the in vivo experiments revealed that the c.620T>G SAS 
was used exclusively, which indicates that this splice site might be particularly 
strong. SASs have an intricate structure as they consist of several sequence elements 
(c.f. Figure 9A). Because of this complexity, the exact parameters defining the 
strength and functionality of SASs remain elusive so far rendering a reliable 
prediction of SAS efficiency rather difficult. To identify the sequence components 
defining the strength of the c.620T>G SAS, its performance was analyzed in an 
independent gene environment. For this purpose, the c.620T>G SAS including 
flanking elements from RHO exon 3 has been introduced into exon 3 of the human 
ribosomal protein S27 (RPS27) minigene (Figure 13A). The native RPS27 exon 3 SAS 
was predicted to be distinctly stronger than the one of the c.620T>G SAS. Therefore, 
an insertion of different c.620T>G SAS sequences into this exon enables a more 
stringent analysis of their splice site strength in comparison to the native RPS27 
exon 3 SAS. Moreover, the native introns and coding exons of RPS27 comprise only 
1330 bp. This convenient size allowed for an expression of the entire gene from 
common expression vectors and the mRNA splicing analysis could thus be 





With this experimental design, a 26 bp long core sequence could be identified, which 
was virtually exclusively used as SAS in exon 3 of RPS27 (Figure 13B). This core 
element, hereafter referred to as SAS_620, contains the SAS, a PPT and a 7 bp 
sequence element upstream of the PPT. Intriguingly, further deletions or insertions 
5’ or 3’ of the SAS_620 reduced the splicing efficiency suggesting the presence and a 
complex interplay of different splice enhancer and silencer sequences in this region. 
 
Figure 13 Splicing of c.620T>G SAS sequences in the RPS27 minigene 
A, Upper panel, Structure of the RPS27 minigene containing all native exons and 
introns. The c.620T>G SAS including flanking sequences of different lengths (RHO_a 
– RHO_g) were introduced into the middle part of RPS27 exon 3. Primers used for 
RT-PCR are shown as black arrows. Lower panel, Individual RHO sequences with the 
PPT depicted in orange and the SAS sequence depicted in pink. B, RT-PCR from 
HEK293 cells transiently transfected with the respective RPS27 minigene. CS, 
correct splicing at the native exon 3 SAS; AS, aberrant splicing at the introduced 
c.620T>G SAS. The top band is a hybrid double strand comprising the correctly and 







4.1.5 Independence of SAS_620 Strength from Gene Environment 
For potential usage in biotechnological applications, the strength and functionality 
of a SAS should be independent of the gene environment. To test whether SAS_620 
fulfills this important requirement, the core element was introduced into four 
additional minigenes, i.e. the hemoglobin subunit theta 1 gene (HBQ1), the S100 
calcium binding protein A12 gene (S100A12), the clarin-1 gene (CLRN1), and the 
cyclic nucleotide gated channel beta 1 gene (CNGB1) (Figure 14A). 
 
Figure 14 Splicing of SAS_620 in independent gene environments 
A, The core element SAS_620 was introduced into the middle exons of minigenes 
originating from five unrelated genes (RPS27, HBQ1, S100A12, CLRN1 and CNGB1) 
and splicing was analyzed via RT-PCR using the indicated primer pairs (black 
arrows). The position of the SAS_620 is marked with a red asterisk. B, RT-PCR of 
HEK293 cells transiently transfected with the respective minigene. nat, minigene 
containing the native splice site only. 620, minigene containing the inserted SAS_620 
in addition to the native splice site. C, Table indicating the length of the spliced 
transcripts for usage of the native SAS vs. SAS_620.  
The strengths of the respective splice sites competing with SAS_620, i.e. the native 
splice sites of the exons, in which SAS_620 was inserted, were predicted using 
different splicing prediction software tools (Table 13). The strengths of these native 





the strengths predicted for the same splice site depending on the used software. 
Nevertheless, SAS_620 was recognized by the splicing machinery in all cases and 
appears to be used exclusively independent of the gene environment or the 
predicted splice site strength (Figure 14B, C). 
Table 13 Predicted SAS strengths using different prediction software 
tools 
SAS strength ranges from 0 to 100 for NNSplice and HSF with 100 indicating highest 
possible strength. ASSP calculates scores using position specific score matrices, 
where higher values indicate higher scores. 
SAS NNSplice HSF ASSP 
RHO_E3 95 90 9.20 
RHO_SAS_620 91 92 11.48 
RPS27_E3 99 96 12.71 
HBQ1_E2 92 95 9.44 
S100A12_E2 97 86 9.57 
CLRN1_E1 86 90 9.40 
CNGB1_E15 77 85 3.96 
 
To test whether the strength of SAS_620 is depending on the cell type, the respective 
minigenes were also transiently expressed in mouse embryonic fibroblasts (MEFs). 
Again, SAS_620 is preferred over the native SAS and appears to be used almost 
exclusively in all cases (Figure 15). Collectively, these findings suggest that SAS_620 
is an exceptionally strong and efficient splicing element. 
 
Figure 15 Splicing of SAS_620 in mouse embryonic fibroblasts 
A, The minigenes containing the SAS_620 (RPS27, HBQ1, S100A12, CLRN1 and 
CNGB1, cf. Figure 14) were transiently expressed in mouse embryonic fibroblasts 
and splicing was analyzed via RT-PCR. nat, minigene containing the native splice site 
only. 620, minigene containing the inserted SAS_620. B, Table indicating the length 






In the experiments conducted so far, the SAS_620 was always tested in an exonic 
environment. However, it is conceivable that the native splice site upstream of 
SAS_620 might be recognized first and that its presence or the presence of other 
exon-defining splice elements could be contributing to the remarkable performance 
of SAS_620. This possibility would limit a broad usage of SAS_620 for 
biotechnological applications. Therefore, the functionality of SAS_620 was tested in 
an intronic region, where no exon-defining elements or upstream splice sites are 
expected to exist. For this purpose, the core element was introduced into the WT 
RHO minigene upstream of the native exon 3 SAS. Importantly, the SAS_620 was also 
exclusively utilized by the splicing machinery in this intronic context (Figure 16). 
 
Figure 16 Introduction of SAS_620 into RHO intron 2 
A, SAS_620 was introduced into the WT RHO minigene upstream of the native exon 
3 SAS at the indicated position (c.532-68). B, Upper panel, HEK293 cells were 
transiently transfected with the WT, the c.620T>G and the c.532-68insSAS_620 
minigene. Lower panel, Splicing was analyzed via RT-PCR using the indicated 
primers. The sequence identity of the splice product for the c. 532-68insSAS_620 







4.1.6 High Flexibility of the c.620T>G SAS in Branch Point Choice 
As shown in Figure 13A, the SAS_620 consists of a SAS, a PPT and an additional 7 bp 
sequence upstream, the deletion of which is impairing SAS_620 recognition. 
Therefore, it seems reasonable to assume that this 7 bp sequence might contain a 
very potent branch point potentially explaining the universal and efficient 
recognition of SAS_620 regardless of the gene environment. However, there were no 
potent branch points predicted within this sequence. Instead, other sequences 
positioned up to 40 bp upstream of the c.620T>G SAS were predicted to serve as 
branch points (Figure 17). Nevertheless, when simultaneously mutating all 
predicted branch point nucleotides and all potential branch point adenines 
contained in the 7 bp sequence upstream of the PPT, splicing could not be altered 
for the c.620T>G mutant (Figure 17B). This finding indicates that the branch 
point(s) are either located elsewhere or that the c.620T>G SAS is highly flexible in 
branch point choice. 
 
Figure 17 Mutation of potential branch points in RHO c.620T>G exon 3 
A, Sequence of the RHO c.620T>G minigene. Potential branch point nucleotides 
within the 7 bp sequence upstream of the PPT or predicted by the HSF software are 
marked with gray boxes. B, Left panel, RT-PCR analysis of the transiently expressed 
RHO WT minigene and two variants of the c.620T>G minigene. In the 





upstream of the c.620T>G SAS have been replaced by guanines or cytosines. Right 
panel, HSF scores for all predicted branch points or for potential branch point 
sequences present in the 7 bp sequence of SAS_620. Branch point nucleotides are 
shown as capital letters. BP, branch point. 
To identify the branch point(s) utilized for splicing at the c.620T>G SAS more 
directly, a nested lariat RT-PCR was performed using HEK293 cells transiently 
expressing the RHO c.620T>G minigene (Figure 18A). HEK293 cells transfected with 
the RHO WT minigene served as a reference. When performing the lariat RT-PCR, 
one band was obtained for the WT and for the mutant minigene, respectively, both 
differing in their size. Both bands appeared somewhat diffuse suggesting that they 
contained lariats of varying size. To identify the single sequences contained in these 
diffuse bands, the lariat RT-PCR products were subcloned into a TOPO vector and 
the obtained clones were analyzed individually via sequencing. When investigating 
the RHO WT lariats, two major branch points (used in 42 % and 33 % of cases) and 
three minor branch points (8 % of cases each) were identified (Figure 18B). The two 
major branch points closely resembled the consensus sequence and yielded high 
prediction scores (Table 14). All RHO WT branch points were found 57 – 184 bp 
upstream of the intron-exon junction. As more than 90 % of human branch points 
are found within 50 bp upstream of the SAS sequence, mRNA splicing of RHO exon 3 
seems to be somewhat unconventional (Corvelo et al., 2010). 
 
Figure 18 Identification of branch points via nested lariat RT-PCR 
A, Upper panel, RHO minigene expressed for nested lariat RT-PCR. The used primer 
pairs are depicted as light and dark blue arrows. Lower panel, Minigene after lariat 
formation via branching at the indicated branch point nucleotide. B, Partial 





(black lowercase). The respective SAS is indicated via a pink box. Identified branch 
point sequences are depicted underlined and bold with the branch point nucleotide 
shown as a capital letter. The frequency of the identified branch point is shown 
above or below the respective sequence. 
Table 14 Detected branch points and corresponding prediction scores 
RHO WT minigene 
Branch point Relative position HSF score Frequency of usage 
cactgAt -184 bp 84.3 41.6 % 
tccacAa -177 bp 76.8 8.3 % 
tccccAt -158 bp 85.6 33.3 % 
ttatgAt -113 bp 60.6 8.3 % 
cagccAc -57 bp 58.4 8.3 % 
RHO c.620T>G minigene 
atcgAt -245 bp 83.6 16.7 % 
attccAt -236 bp 55.6 8.3 % 
tgcagAc -213 bp 73.9 8.3 % 
cgtttAt -208 bp 55.9 8.3 % 
atcccCt -200 bp not predicted 16.7 % 
cagggAg -189 bp not predicted 8.3 % 
gaagcCc -174 bp not predicted 8.3 % 
ttcccAa -132 bp 79.5 8.3 % 
caggcAg -118 bp not predicted 8.3 % 
tccctAc -107 bp 77.6 8.3 % 
 
Nevertheless, the branch point profile obtained for RHO c.620T>G was remarkably 
different when compared to the WT minigene. First, various branch points have 
been identified for the c.620T>G mutant. However, no major branch point(s) could 
be detected and none of them were identical with the ones obtained for the WT 
minigene. Second, the branch points were located even further upstream from the 
used SAS, i.e. 107 – 245 bp corresponding to 21 – 159 bp upstream of the native exon 
3 SAS. Third, almost half of the detected branch points hardly resembled the 
consensus sequence and accordingly were not predicted by the Human Splicing 
Finder (HSF) splice prediction tool. All in all, these data suggest that the strength of 
SAS_620 does not originate from the presence of a contained, very potent branch 





could explain its unusually efficient performance and renders it a very attractive tool 
for biotechnological applications requiring efficient splicing. 
4.2 DEVELOPMENT OF A NOVEL DUAL VECTOR TECHNOLOGY USING 
THE SAS_620 SPLICING ELEMENT 
4.2.1 Reconstitution of a Fluorescent Reporter Using mRNA Trans-Splicing 
For reconstitution of full-length coding sequences (CDSs) in the framework of dual 
vector technologies, DNA-based and protein-based reconstitution strategies have 
been employed so far. However, these approaches harbor limitations due to their 
low and unpredictable reconstitution efficiencies or their restricted applicability 
and potential safety issues. Therefore, a novel strategy aiming at reconstitution of 
CDSs at the mRNA level via mRNA trans-splicing has been explored in this study. For 
this purpose, I developed a fluorescent reporter-based assay, for which the CDS of 
the cyan fluorescent protein “cerulean” was split into two halves at c.154 (Figure 
19A). Both parts were equipped with a splice donor (SDS) or acceptor site and a 
complementary binding domain (BD) and were expressed separately under the 
control of a CMV promoter. After transcription, base-pairing of the BDs brings the 
contained splicing elements into close proximity, which facilitates splicing in trans 
and results in a full-length (FL) mature mRNA (Figure 19B). As the SAS_620 should 
be a very suitable splicing element for such an application, it was used on the 3’ 
vector to enable efficient trans-splicing. Furthermore, a SDS yielding the highest 
possible prediction scores was used for the subsequent experiments. Due to their 
low complexity, SDSs are well characterized and the prediction of their strength is 
well-matched on their experimental performance. For initial evaluation, a 100 bp 
sequence originating from the human rhodopsin intron 2 was chosen as a BD.  
HEK293 cells were transiently co-transfected with each CDS half and the presence 
of cerulean fluorescence was evaluated via confocal live cell imaging. A construct 
containing both CDS halves in cis with an intervening artificial intron equipped with 
the same splicing elements was used as cis-splicing reference control (cis-ctrl). 
When the two halves were transfected separately, no fluorescence could be 
detected. By contrast, when co-transfecting both constructs, some fluorescent cells 





cerulean coding sequence (Figure 19C). As a next step, different BDs were tested in 
order to optimize the trans-splicing efficiency. For this purpose, sequences differing 
in their length and their position in the 5’ and the 3’ region of RHO intron 2 were 
used (Figure 20A). Moreover, artificial BDs were created by fusing sequences 
originating from the 5’ and the 3’ end of the intron. A list of all BD sequences tested 
is displayed in section 7.2. 
 
Figure 19 Schematic illustration of the reporter assay used for evaluation 
of gene reconstitution via mRNA trans-splicing 
A, Reporter genes used for evaluation of the mRNA trans-splicing dual vector 
approach.  The coding sequence of the fluorophore “cerulean” was split into two 
halves and equipped with all elements necessary for trans-splicing, i.e. 
complementary binding domains (BD and BDrev, rev: reverse complement) and a 
splice donor (SDS) or acceptor site (SAS). A cis-spliced cerulean construct (cis-ctrl) 
containing an artificial intron served as a positive control. B, pre-mRNA from 5’ 
vector- and 3’ vector-constructs. After successful trans-splicing of both molecules, 
the FL cerulean mRNA is reconstituted. C, Confocal live imaging of HEK293 cells 
transiently transfected with the respective reporter gene(s). The presence of 






Figure 20 Binding domain optimization for increase in reconstitution 
efficiency 
A, Schematic illustration of RHO intron 2 sequences tested as BDs (a – h). B, BD-
mediated binding of both pre-mRNA molecules before trans-splicing. C, Confocal live 
cell imaging of HEK293 cells co-transfected with the 5’ vector- and the 3’ vector-
constructs containing the respective binding domains (BD_a – BD_h). cis-ctrl, cis-





When co-transfecting HEK293 cells with constructs containing the respective 
binding domains, a great variance in the amount of cerulean fluorescence could be 
observed indicating great variability in the corresponding trans-splicing efficiencies 
(Figure 20B, C). Consequently, the binding domain sequence seems to be an 
important element for efficient reconstitution. Next, the precision of the trans-
splicing process was analyzed via RT-PCR. With this approach, no unspecific bands, 
which might arise from usage of alternative splice sites present in the expression 
cassette, could be detected (Figure 21A, B). Accordingly, sequencing revealed that 
all constructs were spliced exactly at the splicing elements as intended (Figure 21C). 
Collectively, these findings suggest that trans-splicing is a seamless and precise 
process reliably restoring the split reading frame.  
 
Figure 21 Evaluation of trans-splicing precision and reconstitution 
efficiency 
A, FL cerulean mRNA was detected via RT-PCR using the indicated primer pair 
(black arrows). Cerulean protein was detected by western blotting using an anti-
GFP antibody capable of detecting cerulean (α-cer). B, RT-PCR from HEK293 cells 
co-transfected with the respective 5’ and 3’ vector containing BD_a – BD_h. Ø, 
untransfected cells. GAPDH was amplified as a loading control. C, Representative 
sequencing result of the reconstituted cerulean. D, Western blot of protein lysates 
from co-transfections using the single BD combinations (BD_a – BD_h). Beta tubulin 
served as a loading control. E, Reconstitution efficiencies were determined via a 
ratiometric analysis of the cerulean protein band intensities in relation to the cis-
ctrl (n = 3 – 8). All protein bands were normalized to beta tubulin prior to 





For quantification of the reconstitution efficiencies, the amount of cerulean protein 
was determined via western blotting. When compared to the cis-ctrl, reconstitution 
efficiencies of 62.3 % ± 7.9 % could be obtained (Figure 21D, E). The BDs yielding 
the highest efficiencies are both composed of approximately 100 bp. One of them 
(BD_h) is an artificially created fusion domain consisting of a 5’ and a 3’ intronic part, 
whereas the second one (BD_e) is representing a region in the 3’ part of RHO intron 
2. The calculated reconstitution efficiencies are exceeding the best in vitro 
efficiencies reported for DNA-based reconstitution so far (Carvalho et al., 2017) and 
are comparable to the in vitro efficiencies obtained for split intein based 
reconstitution at the protein level (Chew et al., 2016, Tornabene et al., 2019) 
4.2.2 Impact of Splice Acceptor Site vs. Binding Domain on Reconstitution 
Efficiency 
As shown in 4.2.1, the BD length and sequence represent key determinants for the 
reconstitution efficiency. The BDs most likely influence the tight binding and, 
potentially, the folding of the mRNAs, but they are not expected to directly facilitate 
the efficiency or precision of the subsequent splicing process. As mentioned above, 
SDSs are well characterized and the prediction of their strength is well-matched on 
their experimental performance. Consequently, there is no apparent need for 
optimization of this splice site in the framework of the split fluorophore 
reconstitution assay. By contrast, due to their complexity, the strength of the SASs 
cannot be reliably predicted (cf. 4.1.4 and 4.1.5). The results shown in 4.1 suggest 
that SAS_620 is an exceptionally strong splice acceptor site. Given that the splice site 
strength can impact on the reconstitution efficiency of the split fluorophore assay, 
SAS_620 should lead to higher values when compared to other SASs. To analyze this, 
the reconstitution efficiencies in presence of SAS_620 or two other SASs, i.e. the 
native SAS of RHO exon 3 (S3, cf. Figure 14) and a hybrid SAS (S2) which was created 
by replacing the PPT of SAS_620 with the PPT of the native RHO exon 3 SAS, were 
compared. Moreover, each SAS was combined with each of three different binding 
domains: a strong (BD_e, B1) and a weak (BD_c, B3) binding domain originating 
from this study and a published BD sequence (PTM1, B2) obtained from RHO intron 
1. The last sequence was shown to yield high efficiencies for the repair of mutated 





2015). All combinations were analyzed via confocal live cell imaging, RT-PCR and 
western blotting (Figure 22). 
 
Figure 22 Impact of SAS vs. BD on reconstitution efficiency 
A, BDs and SASs tested in this experiment. All BD sequences originate from the 
human RHO gene. BDs and SASs expected to yield high efficiencies are highlighted 
in red. B, Confocal live images of HEK293 cells transfected with constructs 
containing different combinations of the three BDs and the three SASs. The strength 
of the respective BD and SAS is indicated. Scale bar, 50 µm. C, Upper panel, RT-PCR 
of the different BD and SAS combinations. Lower panel, Western blot of the different 
BD and SAS combinations. GAPDH and beta tubulin served as loading controls. D, 
Quantification of the reconstitution efficiency by the ratiometric analysis of the 
cerulean protein bands in relation to the cis-ctrl (n = 3 – 8). All protein bands were 
normalized to beta tubulin prior to quantification. Reconstitution efficiency values 
for each combination can be found in 7.3. 
This experiment resulted in several important findings. First, it revealed that both, 
the BD and the SAS are key components determining reconstitution efficiencies. 
Second, the most potent BD identified in this study (BD_e, B1) outperforms the 
published RHO binding domain (B2). Third, the SAS strength appears to influence 
the reconstitution efficiencies even more potently than the BD, as the weakest BD 





whereas the strongest BD combined with the weakest SAS (B1+S3) does not lead to 
a detectable reconstitution of the CDS. 
4.2.3 Reconstitution via mRNA Trans-Splicing in Different Cell Types 
Splicing can vary between different cell types, as it is a highly tissue-specific process 
(Arias et al., 2010). For a broad application of mRNA trans-splicing dual vectors, high 
reconstitution efficiencies need to be achieved irrespective of the target tissue. To 
address the cell type dependency of the split fluorophore reconstitution assay, the 
best BDs (BD_e and BD_h) in combination with the best SAS (S1) were tested for 
their reconstitution efficiency in 661W cells and in MEFs. As controls, a weak BD 
(BD_g) combined with a strong SAS (S1) and a strong BD (BD_e) combined with a 
weak SAS (S3) were used. 
 
Figure 23 Reconstitution via mRNA trans-splicing in different cell types 
A, Confocal live cell images of 661W cells and MEFs transiently transfected with 
constructs containing different BDs (BD_e, BD_h or BD_g) and SASs (S1 or S3). Scale 





C, Quantification of the reconstitution efficiency based on the ratiometric analysis of 
the western blot band intensities (n = 3 – 8). For statistical testing, one-way ANOVA 
was applied. Reconstitution efficiency values for each combination can be found in 
7.3. 
Successful reconstitution could be observed via confocal live cell imaging and via 
western blotting for both cell types (Figure 23A, B). BD_e and BD_h in combination 
with S1 yielded high reconstitution efficiencies, i.e. 44.7 % ± 12.0 % and 31.5 % ± 
6.6 % in 661W cells and 52.6 % ± 20.0 % and 41.7 % ± 5.4 % in MEFs (Figure 23C). 
No significant difference in trans-splicing efficiencies could be detected when 
comparing all three cell types. This suggests that the mRNA trans-splicing approach 
is cell type independent. 
4.2.4 Investigation of mRNA Trans-Splicing-Based rAAV Dual Vectors in Vivo 
The most potent application of the mRNA trans-splicing-based assay evaluated in 
the previous sections is the reconstitution of large genes in the framework of dual 
rAAV vectors. Consequently, the mRNA trans-splicing approach was tested in the 
mouse retina using rAAVs. For this purpose, a slightly modified version of the split 
fluorophore assay was used. To control the rAAV vector-born expression in the cells 
transduced with the single viruses, both dual rAAV vector cassettes were equipped 
with a fluorophore sequence, i.e. a citrine at the 5’ end of the CDS for the 5’ vector 
and a mCherry at the 3’ end of the CDS for the 3’ vector. One of the BDs yielding the 
highest reconstitution efficiencies in vitro, i.e. BD_h, was used in vivo (Figure 24A). 
In this experimental setup, cerulean fluorescence should be present in cells 
expressing citrine as well as mCherry. The titer-matched viruses were injected 
subretinally on P21 into WT C57Bl6/J mice. After harvesting the retinas two weeks 
post-injection, a solid fluorophore expression could be detected in the RPE (Figure 
24B). Moreover, cerulean fluorescence could be observed in all areas where citrine 
and mCherry were expressed indicating successful mRNA trans-splicing in cells co-
transduced with both AAVs. However, citrine and cerulean possess partially 
overlapping excitation and emission spectra. To exclude the possibility of the 
cerulean fluorescence being an artefact caused by e.g. bleed-through of citrine or 
mCherry, both fluorophores were bleached selectively in a small area of the RPE by 





the citrine and mCherry fluorescence could be removed completely (Figure 24C). 
Nevertheless, the cerulean fluorescence remained unchanged indicating that it 
originates solely from trans-spliced cerulean mRNA. This experiment provides proof 
of principle for the usability of mRNA trans-splicing for reconstitution of genes 
expressed from AAVs in vivo. 
 
Figure 24 mRNA trans-splicing rAAV dual vector approach in vivo 
A, 5’ vector- and 3’ vector-constructs used for in vivo expression. As an expression 
control, a citrine and a mCherry sequence was fused 5’ of the cerulean 5’ CDS and 3’ 
of the cerulean 3’ CDS, respectively. Start and stop codons are indicated by traffic 
lights. ITR, inverted terminal repeats. B, Representative confocal images of retinal 
sections harvested two weeks post-injection expressing constructs containing BD_h. 





outer nuclear layer. Scale bar, 20 µm. C, Confocal images of RPE cells before (upper 
panel) and after (lower panel) selective photobleaching of citrine and mCherry 
fluorophores using a 514 nm laser. Scale bar, 2 µm. 
4.2.5 Identification of Potent Binding Domain Suitable for Human Gene 
Therapy 
So far, all BD sequences were obtained from human intronic regions. When used for 
human gene therapy, they thus could potentially also bind to endogenous mRNAs 
and induce trans-splicing with these transcripts. It is therefore necessary to find 
identify BDs which do not contain sequences homologous to the human genome. For 
this purpose, a random 100 bp sequence was taken from the bacterial lacZ gene and 
modified via random insertions, deletions and substitutions to obtain four 
sequences without any homology to the human genome (Figure 25A). When co-
transfecting HEK293 cells with the 5’ vector- and 3’ vector-constructs containing the 
respective binding domains, very high cerulean reconstitution efficiencies of 78.3 % 
± 2.1 % could be observed for one of the BDs (BD_ j, Figure 25B – D). BD_ j was thus 
more efficient than the best performing human BDs shown in Figure 21 and was 
therefore used for preliminary experiments evaluating reconstitution of large genes 
via mRNA trans-splicing. 
 
Figure 25 Identification of suitable BDs originating from lacZ gene 
A, BDs taken from the bacterial lacZ gene and modified to possess no detectable 
homology to the human genome. B, Confocal live images of HEK293 cells transiently 





Western blot obtained from transfected HEK293 cell lysates. Quantification of 
reconstitution efficiency based on the ratiometric analysis of the western blot band 
intensity (n = 3 – 8). BD_e efficiency served as a measure for the highest 
reconstitution obtained so far. Reconstitution efficiency values for each BD can be 
found in 7.3. 
4.2.6 Proof of Principle for Reconstitution of Large Genes via mRNA Trans-
Splicing 
So far, only the cerulean split reporter assay has been used for evaluation of mRNA 
trans-splicing. A suitable candidate for investigating mRNA trans-splicing on a large 
gene is a recently developed novel tool for gene therapy: the transcriptional 
activator SpCas9-VPR, a catalytically inactive nuclease fused to the transcriptional 
activator domains VP64-p65-Rta (VPR). Due to its large size (5.8 kb), it needs to be 
delivered via dual vectors for in vivo applications. 
 
Figure 26 Reconstitution of SpCas9-VPR 
A, Constructs designed for reconstitution of SpCas9-VPR. The full-length (FL) 
construct was used as a positive control. A junction-spanning primer pair was used 
for RT-PCR (black arrows). B, RT-PCR from three independent transfections of 
HEK293 cells with the respective construct(s). C, Sequencing result of the 






The CDS of SpCas9-VPR was split into two halves at c.2185 and the two CDS halves 
were equipped with BD_ j and the appropriate splicing elements, i.e. the SDS or the 
SAS (Figure 26A). A FL SpCas9-VPR construct was used as a positive control. The 
RT-PCR from HEK293 cells co-transfected with the split constructs revealed that 
SpCas9-VPR mRNA was reconstituted successfully and that no unwanted side-
products were generated (Figure 26B). Sequencing of the PCR product confirmed an 
accurate restoration of the reading frame (Figure 26C). Moreover, FL SpCas9-VPR 
protein could be detected via western blotting (Figure 26D). The reconstitution 
efficiencies of SpCas9-VPR were 13.2 % ± 0.9 %. This provides a proof of principle 









5.1 IMPLICATIONS OF C.620T>G MUTATION CREATING A SPLICE 
ACCEPTOR SITE WITH UNIQUE PROPERTIES 
In this study, strong evidence is provided that the deep exonic adRP mutation 
c.620T>G is a splicing mutation which has been misclassified as a missense mutation 
since its discovery. For the development of adequate treatment strategies, it is 
important to understand the molecular mechanism underlying a disease-linked 
mutation. Exonic point mutations are generally expected to affect key amino acid 
residues and are therefore categorized as missense mutations. However, as already 
proposed in previous studies (Becirovic et al., 2016b, Soukarieh et al., 2016), the 
findings of this study suggest that an underestimated number of such mutations 
might instead impact on mRNA splicing. This conclusion is of particular importance, 
as mRNA splicing might be a so far misjudged molecular factor markedly influencing 
the pathogenicity of various disease-causing mutations. Moreover, this finding 
shows that the effect of exonic mutations at the mRNA level should be investigated 
before their final classification as missense mutation. Such an examination can help 
to avoid the elaborate analysis of mutant proteins which do not naturally exist. 
Additionally, such investigations can help to potentially clarify other puzzling 
differences in disease courses caused by similar mutations at the molecular level. 
Lastly, this finding could improve the understanding of genotype-phenotype 
correlations thereby potentially refining disease course predictions in affected 
patients in the framework of genetic counselling. 
The results obtained in this study indicate that the adRP phenotype severity in 
patients carrying mutations in the coding region of Met207 and in surrounding 
areas is correlating with the number of affected amino acids. Patients affected by the 
c.620T>A mutation, in which only one amino acid, i.e. Met207, is altered, exhibit a 
mild, late-onset adRP phenotype (Audo et al., 2010a, Audo et al., 2010b). By contrast, 
the c.614-622del mutation causing the deletion of three aa leads to an intermediate 
phenotype (Maubaret et al., 2012) and the c.620T>G mutation resulting in a deletion 
of 30 aa correlates with a severe, early-onset disease variant. However, the exact 





be elucidated. One possible mechanism already shown for other severe rhodopsin 
mutants, e.g. for P23H, is that c.620T>G might result in protein misfolding, 
aggregation and gain-of-function effects (Athanasiou et al., 2018). 
Met207 has been found to be an important aa residue in the ligand binding pocket 
of GPCRs (Moitra et al., 2012). Therefore, it has been assumed that the main reason 
for the puzzling adRP phenotype difference associated with the c.620T>G and the 
c.620T>A mutations originates from their differential impact on binding of the 
ligand, i.e. 11-cis-retinal, in rhodopsin. However, a recent study failed to provide 
conclusive evidence supporting this hypothesis (Audo et al., 2010a). Here, I show 
that a completely different molecular mechanism is underlying the differential 
disease courses of these mutations. Moreover, it was demonstrated that the 
Met207Arg protein does not naturally exist rendering an investigation of the impact 
of this aa exchange on ligand binding obsolete. This finding again highlights the 
importance of examining the impact of disease-linked mutations on mRNA splicing. 
Another interesting finding of this study is the fact that the c.620T>G mutation is 
creating an exceptionally strong SAS, as it is exclusively used independent of the 
gene environments and cell types tested herein. Furthermore, I could identify a 26 
bp sequence, termed SAS_620, as the core element responsible for this strength. This 
sequence could be a suitable tool for biotechnological applications requiring strong 
splicing elements like spliceosome-mediated mRNA trans-splicing (SMaRT) (Berger 
et al., 2016), mirtrons (Curtis et al., 2012) or gene trapping (Stanford et al., 2001). 
The exact mechanism defining the extraordinary strength of SAS_620 remains to be 
investigated. One possible explanation is the presence of efficient intronic splice 
enhancer (ISE) motifs. A recent study focused on characterizing such human ISE 
elements and defined six distinct groups (A – F) (Wang et al., 2012). Indeed, two of 
these ISE motives are present in the first 7 bp of the SAS_620, i.e. AACG (group F) 
and CGAG (group D). Another interesting characteristic of the c.620T>G SAS is its 
flexibility in branch point choice. The underlying molecular mechanism and 
sequence elements facilitating this process have yet to be elucidated. Generally, SAS 
strength can be predicted using different prediction software tools. Nevertheless, 
little is known about how accurately these predictions can be matched with 





strength and experimental findings could be identified, indicating that current 
algorithms cannot reliably predict SAS performance yet. Based on the results of this 
study, it is tempting to speculate that the flexibility in branch point choice is another 
property influencing SAS strength and therefore needs to be considered for such 
predictions. 
Collectively, these data identify mRNA splicing as an important disease mechanism 
most likely responsible for the severe adRP phenotype in patients harboring the 
c.620T>G mutation. Therefore, it seems reasonable to test other mutations in other 
genes for a potential impact on mRNA splicing. Finally, the SAS_620 could be a useful 
tool for biotechnological applications requiring strong splice elements. 
5.2 EVALUATION OF NOVEL MRNA TRANS-SPLICING DUAL VECTOR 
APPROACH 
In the second part of this study, a novel dual vector approach based on 
reconstitution via mRNA trans-splicing has been developed. After subtracting 
additional expression elements like promoters, pAs, all elements necessary for 
trans-splicing and flanking ITRs the total packaging capacity of the mRNA trans-
splicing dual vectors amounts to 7.7 kb, which substantially expands the cargo 
capacity of single AAVs. Furthermore, this novel strategy is tackling the major 
limitations of the existing dual vector strategies, which are based on reconstitution 
at the DNA or at the protein level. Genomic reconstitution is mainly limited due to 
its low efficiencies (Duan et al., 2001, Trapani et al., 2014). The mRNA trans-splicing 
dual vectors tested herein were found to yield efficiencies of up to 78 % for 
reconstitution of a reporter gene in vitro. This value is by far exceeding the 
efficiencies obtained for genomic in vitro reconstitution of a reporter gene via the 
overlapping, genomic “trans-splicing” or hybrid approach, which range between 10 
% and 18 % (Duan et al., 2001, Carvalho et al., 2017). Surprisingly, the reconstitution 
efficiencies were even higher than the ones reported for the well-performing split 
intein strategy, which yields about 55 % reconstitution of a reporter gene in vitro 
(Tornabene et al., 2019). However, despite providing some initial proof for the 
applicability of the mRNA trans-splicing strategy in vivo, reconstitution efficiencies 





One of the major limitations of the split intein approach is its limited applicability, 
as split sites need to contain suitable aa and lie outside of structural domains to 
avoid improper folding (Tornabene et al., 2019). Therefore, this strategy requires 
extensive optimization steps for every targeted protein, which can be a costly 
endeavor. By contrast, the mRNA trans-splicing approach only requires the 
presence of an AAGGT or a CAGGT motif, which can usually be found abundantly, as 
they are naturally occurring at exon-exon junctions in the CDS. Another limitation 
of the split intein vectors is the continuous expression of the bacterial intein protein, 
which could potentially raise safety concerns. By contrast, all bacterial sequences 
contained in the mRNA trans-splicing vectors are removed during splicing and 
should consequently not lead to the expression of any bacterial protein. 
The mRNA trans-splicing strategy is potentially also suitable for triple vector 
reconstitution, which would expand the packaging capacity even further. As efficient 
co-transduction of retinal cells by three AAVs has already been shown (Maddalena 
et al., 2018), this would open up new treatment options, e.g. for patients with 
mutations in genes requiring more than two vectors like CDH23. In this context, 
trans-splicing in the correct order and orientation could be ensured by using 
different BDs for the two trans-splicing events. However, in these triple vector-
based approaches the overall reconstitution efficiency is expected to be reduced and 
needs to be thoroughly evaluated. 
In 5.1, I postulated that the SAS_620 could be a suitable tool for biotechnological 
applications. By successfully employing the SAS_620 for mRNA trans-splicing-based 
reconstitution of genes, I provided experimental proof supporting this hypothesis. 
Moreover, the capability of the SAS_620 to facilitate high reconstitution efficiencies 
was compared to the performance of the native RHO exon 3 SAS. In this setting, 
SAS_620 vastly outperformed the native SAS, as the latter was not able to generate 
detectable amounts of reconstituted protein. 
Despite the numerous advantages of the mRNA trans-splicing dual vector 
technology listed above, this strategy also harbors potential limitations. For 
instance, in contrast to the classical dual vectors used for reconstitution at the 
genomic level, the second expression cassette requires the presence of a promoter, 





vectors used for genomic reconstitution also lack the regulatory pA sequence in the 
5’ vector. This implies a reduced risk of expressing truncated proteins from the split 
CDS contained in this vector. For the mRNA trans-splicing approach, both mRNAs 
could potentially be translated into truncated proteins. However, translation from 
mRNA originating from the 3’ vector is less likely, as this transcript usually does not 
contain a suitable start codon. Moreover, the likelihood for translation of the mRNA 
originating from the 5’vector into truncated protein can be decreased by deleting 
the pA. Nevertheless, it remains to be evaluated, whether this modification is 
reducing the reconstitution efficiency. Furthermore, potential adverse effects of the 
expression of such truncated proteins in the target tissue need to be investigated. 
However, most diseases suitable for gene supplementation therapy follow a 
recessive mode of inheritance. In these cases, healthy individuals heterozygous for 
the respective mutations constantly express the non-functional proteins. For these 
diseases, a presence of truncated proteins is therefore not expected to have 
detrimental effects in the affected tissue. 
In this study, I show that mRNA trans-splicing is a highly efficient and precise 
process suitable for reconstitution of genes in vitro. Moreover, when using AAV 
vectors for gene delivery, I demonstrated that this technology is applicable in vivo. 
Finally, I provide a proof of principle for reconstitution of the SpCas9-VPR module 
in vitro. However, the SpCas9-VPR reconstitution efficiency was reduced when 
compared to those obtained for the reporter gene. One possible limiting factor 
contributing to this finding might be the bacterial origin of this gene. In fact, the 
SpCas9-VPR mRNA might not resemble human transcripts closely enough to be 
recognized efficiently by the splicing machinery. 
A possibility to increase the amount of trans-spliced transcript could be the 
introduction of small introns into the CDS to mimic the structure of native 
eukaryotic pre-mRNAs, which in turn might recruit the splicing machinery into 
proximity of the splicing elements used for trans-splicing. Other options for 
increasing the amount of reconstituted protein are the introduction of intronic 
splice enhancer elements or the addition of more potent regulatory elements like 
the woodchuck hepatitis virus posttranscriptional regulatory element. However, the 





efficiencies for large genes need to be investigated in vivo. Very similar to the hybrid 
dual AAV vectors, the mRNA trans-splicing AAV vectors contain a binding domain 
and splice elements. Therefore, one can assume that these vectors might be capable 
of reconstitution at the genomic level in addition to the mRNA level, which could 
further increase the amount of reconstituted protein in vivo.  
Collectively, in this study, I demonstrate that the dual mRNA trans-splicing vector 
strategy is an efficient and precise approach for reconstitution of genes in vitro and 
in vivo. By combining an efficient reconstitution with a safe and universally 
applicable vector design, this strategy offers many advantages over the commonly 
used dual vector technologies and therefore holds the potential to further expand 
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7.1 LIST OF RT-PCR PRIMERS 
Primer Sequence 
RHO exon 1 forward 5’ GCTTCTTTGCCACCCTGGGCG 3‘ 
Citrine reverse 5’ TCCTCGCCCTTGCTCACCAT 3‘ 
Myc-tag reverse 5’ CCTCTTCTGAGATGAGTTTTTG 3’ 
pcDNA3.1 forward 5‘ ACTATAGGGAGACCCAAGCTG 3‘ 
pcDNA3.1 reverse 5‘ AGGCTGATCAGCGGGTTTAA 3‘ 
RPS27 forward 5‘CGACCTACGCACACGAGAAC 3‘ 
RPS27 reverse 5‘ CGACCTACGCACACGAGAAC 3‘ 
HBQ1 forward 5’ TGGAAGAAGCTGGGCAGCAA 3’ 
S100A12 forward 5‘ AAACCTTCCTTGGCTCAGTG 3‘ 
CLRN1 reverse 5‘ TTGAGCCTGGTGCCTGGTA 3‘ 
CNGB1 forward 5’ CCAACTCAGAGAGCTGCTCCG 3‘ 
Lariat 1 forward 5‘ GGCATAGCCCTAGCCTCAGC 3‘ 
Lariat 1 reverse 5’ TTCTGCCCTACACCCCTACC 3’ 
Lariat 2.1 forward 5‘ GCGACACTGATTCCACAAGGT 3‘ 
Lariat 2.1 reverse 5’ CTGGAGGACCCTACAAAGAGC 3’ 
Lariat 2.2 forward 5‘ ATGCTGGGGCTGGGCATG 3‘ 
Lariat 2.2 reverse 5’ TTTGGGCCAGGAGACATACAAGG 3’ 
Cerulean forward 5‘ ATGGTGAGCAAGGGCGAGG 3‘ 
Cerulean reverse 5’ CTTGTACAGCTCGTCCATGCC 3’ 
SpCas9 forward 5‘ AGAACGCTTGAAAACTTACGCT 3‘ 

















































AGG 3’ (100bp) 
d 
5‘CCTCCAGTCAGGACTCAAACCCAGTAGTGTCTGGTTCCAGGCACTGAC








AGGG 3‘ (102 bp) 
f 
5’GTTAACCCTCCAGTCAGGACTCAAACCCAGTAGTGTCTGGTTCCAGGC















































Reconstitution efficiency  
(mean ± SEM) 
n Depicted 
in 
BD_a + SAS_620 3.6 % ± 3.5 % 3 Figure 21 
BD_b + SAS_620 29.2 % ± 6.0 % 3 Figure 21 
BD_c (B3) + SAS_620 7.6 % ± 2.3 % 4 Figure 21 
BD_d + SAS_620 45.8 % ± 5.5 % 3 Figure 21 
BD_e (B1) + SAS_620 62.3 % ± 7.9 % 8 Figure 21 
BD_f + SAS_620 45.4 % ± 9.5 % 4 Figure 21 
BD_g + SAS_620 20.6 % ± 5.1 % 3 Figure 21 
BD_h + SAS_620 52.6 % ± 10.1 % 6 Figure 21 
B_e (B1) + S2 4.4 % ± 2.5 % 3 Figure 22 
B_e (B1) + S3 0 % ± 0 % 3 Figure 22 
B2 + SAS_620 (S1) 40.7 % ± 19.9 % 4 Figure 22 
B2 + S2 35.6 % ± 1.5 % 3 Figure 22 
B2 + S3 0 % ± 0 % 3 Figure 22 
B_c (B3) + S2 0 % ± 0 % 3 Figure 22 
B_c (B3) + S3 0 % ± 0 % 3 Figure 22 
BD_i + SAS_620 36.4 % ± 8.8 % 3 Figure 25 
BD_ j + SAS_620 78.3 % ± 2.1 % 3 Figure 25 
BD_k + SAS_620 43.4 % ± 2.2 % 3 Figure 25 
BD_l + SAS_620 21.2 % ± 6.5 % 3 Figure 25 
661W 
BD_e + SAS_620 (S1) 44.7 % ± 12.0 % 4 Figure 23 
BD_h + SAS_620 (S1) 31.5 % ± 6.6 % 4 Figure 23 
BD_g + SAS_620 (S1) 18.8 % ± 8.7 % 4 Figure 23 
BD_e + S3 0.2 % ± 0.2 % 4 Figure 23 
MEF 
BD_e + SAS_620 (S1) 52.6 % ± 20.0 % 3 Figure 23 
BD_h + SAS_620 (S1) 41.7 % ± 5.4 % 3 Figure 23 





BD_e + S3 0 % ± 0 % 3 Figure 23 
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